Professor Jennifer Martin

Professor Jennifer Martin

Chair of Clinical Pharmacology

School of Medicine and Public Health

Translating research into practice and policy

Optimising choice, dose and timing of medicines for a particular patient are the focus of Professor Jennifer Martin's clinical work and research career.

Jennifer Martin

Professor Jennifer Martin is the Chair of the discipline of Clinical Pharmacology in the School of Medicine and Public Health at the University of Newcastle.

Working in the Hunter New England Local Health District, Jennifer leads a team of pharmacy and medicine experts together with pharmacoepidemiologists and pharmacoeconomists, who work across a number of areas including cancer.

Most often centering on therapeutic drugs, the team look at everything from the design and development of drugs, to the clinical trials process, through to the post-marketing phase, where data is collected on how effective those drugs are in practice, and any side effects they might have.

MEDICAL CANNABIS TRIALS

In July 2015, the NSW government announced Australia's first medical cannabis trial for terminally ill adult cancer patients. The Hunter will serve as a recruitment hub for this study and the UON clinical pharmacology group will lead the dose-finding study in the Hunter, together with UON's Conjoint Professors Stephen Ackland and Katherine Clark.

Although likely to polarise opinion, the study could significantly improve the well being of terminal patients at the end of life.

To be conducted in two phases, the trial will assess the ability of cannabis to relieve symptoms including fatigue, low appetite, altered taste and smell for food, low mood, weight loss, nausea, insomnia and pain relief.

Jennifer believes the team was chosen to run the pharmacology aspects of the cannabis trial due to the long history of excellence in the UON Clinical Pharmacology department (previous Chairs include Emeritus Professor Tony Smith and Professor David Henry), and the high level of analytical support offered by the University of Newcastle, led by Dr Peter Galettis.

In line with her focus on optimising the therapeutic benefits of medication, Jennifer sees this trial as a vital opportunity to assess and quantify a drug already being used by many extremely ill patients.

The first phase of the trial will produce world-class pharmacokinetic analysis and sophisticated modelling to inform drug dosage and frequency of administration.

CHALLENGING CONFOUNDERS

Jennifer dismisses the notion expressed by certain quarters of the community that this trial has more to do with political agenda than patient quality of life.

"At the end of the day, we want our patients to access this drug if it proves effective."

"Identifying exactly what helps, how it helps, how much a patient needs and possible side effects is vital," she says, "especially if those side effects are worse than the symptoms being treated."

The team is sourcing pharmaceutical grade cannabis from commercial suppliers overseas who complete rigorous testing, which rule out contaminants such as mould, and authenticate uniform potency.

To further ensure consistency throughout the trial, vaporisers have been chosen as a method of delivery.

"We know that when you eat cannabis in food, there is a huge variability between the amount that you eat and how much you actually need to feel good," Jennifer explains.

"This depends on what meal you have eaten, other drugs you have taken and how well you are."

"But if you inhale it, it goes straight through the lining of your nose or mouth into the bloodstream," she continues.

"If we can be sure the equipment and potency of the cannabis are uniform, we don't have any confounders muddying our understanding of the relationship between dose and effect in a particular person."

THE ROAD TO RHODES

Jennifer spent her childhood in Wellington, New Zealand, where her initial interest in medicine grew from a love of sport. She decided early on that she would become the doctor who travelled with the New Zealand Olympic team.

While studying at the University of Otago, changes to tertiary funding forced medical students to take out large loans, with interest accruing during their student years. Upon graduating, many began work as doctors in New Zealand, but then moved to the United Kingdom or Australia, to pay off their increasing debt.

"By that stage, my eyes were opened to the issues of unequal access to tertiary education, health care and user pays," she recalls.

In 1993, keen to further understand the consequences of inequity in healthcare access, Jennifer was awarded a prestigious Rhodes Scholarship to study politics, philosophy, and economics at the University of Oxford.

Returning to New Zealand, Jennifer trained as a specialist in pharmacology and internal medicine.

"I like that pharmacology is the study of drugs across all areas."

"You get very broad training, but it is also closely related to those wider issues of access to health care resources and drugs," explains Jennifer.

In 2000, Jennifer went to Melbourne to undertake her PhD from Monash University, examining innate immunity in Type 2 diabetes.  Subsequent postdoctoral work at the Walter and Eliza Hall Institute focused on the function of macrophages with high fat diet.  A stint at the University of Queensland as Head of the Southside Clinical School followed.  Here, Jennifer became involved in medical curricula as a method of broadening the experiences and understanding doctors have about medicine and healthcare.

The opportunity to apply for the Chair of Clinical Pharmacology at the University of Newcastle combined with encouragement from leaders in the field to do so, convinced Jennifer to pursue the clinical pharmacology leadership position in 2013.

TEAM COACH

Jennifer is quick to point out that the entire Pharmacology team is working toward the improvement of patients' lives, not just on the cannabis trial, but on a range of research and community leadership roles in medicines' use.

She sees herself not as someone who must actively manage the work of those she leads, but more of a coach helping her team to reach their goals.

"We have a general understanding that people in this group contribute to clinical and medicines research and service."

"They are in charge of pursuing their own research agenda but we need to provide support and opportunities for that," she explains.

Postgraduate students under Jennifer's supervision are developing a mass spectroscopy library and clinical validation for synthetic drugs of abuse, and developing programs to optimise dose and timing of cancer therapies.

Future research will continue to focus on drug individualisation using drug phenotype data, and developing evidence around biosimilars.

Members of Jennifer's team also have a focus on generating evidence to guide the deprescribing of medications - particularly in people with a lot of comorbidity or at the end of life.

MOTIVATED TO RIGHT WRONGS

An intuitive and award winning teacher, Jennifer's style in the classroom is somewhat unconventional.

"My classes are very interactive because I want the students to think," she says.

"We do everything on the whiteboard so they have to interact."

She laughs as she reflects on her propensity to be diverted by tangents in class, but solemnly states her belief that teaching well involves admitting to past errors to prevent students from repeating them.

"I think one of the most important functions of being a professor is mentoring and training the next generation. I think it is a shame that the university system rewards you so well for research but not for teaching."

Not that Jennifer could ever be accused of lagging in research, or any other aspect of her career.

The practicing physician, teacher, researcher, multiple committee and editorial board member, and mother of four wants you to know she is not as intimidating as she looks on paper.

"I am very aware of the impression I make when I say things like 'I was a Rhodes Scholar'," she reflects.

"I just applied for the scholarship, had a vision of what I wanted to do and I got it. So I don't think of it as any badge of achievement, it was just what I did."

"The experience has cemented a responsibility to do something helpful for the community," Jennifer adds.

"I am motivated, but my motivation is to try and ensure equity of access to opportunities based on merit in a society of entitlement, where some people get preferential treatment."

"I know I can't override thousands of years worth of inequity, but I'm doing it in my own small way and I hope that it eventually has some benefit in terms of access to medicines."

Jennifer Martin

Translating research into practice and policy

Optimising choice, dose and timing of medicines for a particular patient are the focus of Professor Jennifer Martin's clinical work and research career.

Read more

Career Summary

Biography

Professor Martin is a dual trained clinical pharmacologist and practising general physician. She has studied politics and health economics at Oxford University as a Rhodes Scholar and has used this experience to serve on the Pharmaceutical Benefits Advisory Committee, the Economic Subcommittee of the PBAC and other Government and Statewide committees examining appropriate allocation, regulation, safety and efficacy in pharmaceuticals. She is a Member of the Australian Institute of Company Directors (Diploma).

Her PhD (Monash) examined innate immunity in Type 2 diabetes and subsequent postdoctoral work at the Walter and Eliza Hall focussed on the function of macrophages with high fat diet. Her recent research is in the area of clinical development of both novel and old drugs for a variety of diseases and has developed a collaboration with Leiden University using clinical pharmacological methods generally to improve dosing, with EKUT (Germany) in the combined role of therapeutic drug monitoring (TDM) and pharmacogenetics to individualise choice and dose of chemotherapy, and with the National Institutes of Health in identifying and managing synthetic drugs of abuse.

Her current PhD students are researching cannabinoid therapies, targeted cancer therapies, dosing in neonates and therapeutic drug monitoring in clinical care including with antimicrobial therapies. Professor Martin is passionate about teaching in the area of clinical pharmacology and been involved in curriculum development for medical students (Otago, Monash, Queensland and Melbourne Universities) was the recent teaching and learning representative on the STC in clinical pharmacology for the College of Physicians (RACP). She is currently a member of the RACP Policy and Advocacy Committee, the Council of the Australasian Society for Clinical and Experimental Pharmacology and Therapeutics, and a member of the Pharmacology and Therapeutics Advisory Committee of PHARMAC, the sole purchaser for pharmaceuticals in New Zealand.

Research Expertise
Professor Jennifer Martin is Chair of Clinical Pharmacology in the School of Medicine and Public Health at the University of Newcastle and a practicing general physician for the Hunter New England Local Health District. She is also the Director of the Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE), a National Health and Medical Research Council (NHMRC) Centre of Research Excellence.



Qualifications

  • PhD, Monash University
  • Bachelor of Medicine & Surgery, University of Otago - New Zealand
  • Master of Arts, University of Oxford - UK

Keywords

  • Clinical pharmacology
  • Personalized medicine
  • Pharmaceutical pricing and regulation
  • Targeted therapies

Fields of Research

Code Description Percentage
110399 Clinical Sciences not elsewhere classified 20
111204 Cancer Therapy (excl. Chemotherapy and Radiation Therapy) 30
111502 Clinical Pharmacology and Therapeutics 50

Professional Experience

UON Appointment

Title Organisation / Department
Chair of Clinical Pharmacology University of Newcastle
School of Medicine and Public Health
Australia

Academic appointment

Dates Title Organisation / Department
1/09/2015 -  Head, Discipline of Medicine, University of Newcastle School of Medicine & Public Health, Faculty of Health & Medicine, University of Newcastle | Australia
Australia
1/01/2013 -  Membership National Prescribing Service Executive – RADAR
Australia
1/01/2013 -  Membership Diamantina Health Partners Symposium Organising Committee
Australia
1/01/2013 -  Membership IATDMCT Oncology Committee
Australia
1/01/2012 -  Membership Diamantina Health Partners Evidence and Innovation Theme
Australia
1/01/2012 -  Membership Diamantina Health Partners Neuroscience and Recovery Centre Steering Committee
Australia
1/01/2011 -  Editorial Board Journal Clinical Toxicology
Australia
1/01/2011 -  Membership IATDMCT Standard Laboratory Practices (SLP) committee
Australia
1/01/2011 -  Membership Queensland Health Improving Presribing Steering Committee
Australia
1/01/2010 -  Editorial Board British Journal of Clinical Pharmacology
Australia
1/01/2010 -  Editorial Board Therapeutic Advances in Drug Safety
Australia
1/01/2010 -  Membership Association of Scientific and Clinical Pharmacologists and Toxicologists
Australia
1/01/2010 -  Membership Australian Society of Clinical and Experimental Pharmacologists and Toxicologists
Australia
1/01/2010 -  Membership Clinical Advisory Group “Closing the Divide in Indigenous Cancer” Queensland Institute Medical Research
Australia
1/01/2010 -  Membership Editorial Advisory Group National Prescribing Service
Australia
1/01/2010 -  Membership PAH Clinical Council
Australia
1/01/2010 -  Membership UQ Discipline of Medicine Research Symposium Organising Committee and Sessional Chair
Australia
1/01/2010 -  Membership University of South Australia Sansom Institute Research Advisory Board
Australia
1/01/2009 -  Membership Medical Journal of Australia (MJA) Insight; Australian Doctor
Australia
1/01/2008 -  Membership QH Medicines Advisory Committee
Australia
1/01/2008 -  Membership Queensland Health Medicines Advisory Committee
Australia
1/01/2007 -  Editorial Board Australian Prescriber
Australia
1/01/2007 -  Editorial Board Internal Medicine Journal
Australia
1/01/2007 -  Membership Pharmacogenetics; Education ASCEPT (SIG)
Australia
1/01/2007 -  Membership Medical Observer
Australia
1/01/2006 -  Editorial Board Australian Medicine Handbook
Australia
1/01/2005 - 31/12/2009 Membership Therapeutic Guidelines Working Group
Australia

Awards

Recipient

Year Award
2014 Finalist Royal Australasian College of Physicians Teaching Award
Royal Australiasian College of Physicians (RACP)
2010 Finalist Clinical Educator of the Year
Postgraduate Medical Council Queensland (Australia)
2010 Nominee Teaching Award for Junior Medical Staff
PA (Princess Alexandra Hospital) Health Symposium

Recognition

Year Award
1999 "Best Registrar" teaching award for 5th year medical students
Christchurch School of Medicine, Otago University (New Zealand)
1998 "Best Registrar" teaching award for 4th year medical students
Christchurch School of Medicine, Otago University (New Zealand)

Research Award

Year Award
2014 University of Queensland Teaching Award
RBWH Clinical School, Faculty of Health Sciences, University of Queensland (Australia)
Edit

Publications

For publications that are currently unpublished or in-press, details are shown in italics.


Chapter (17 outputs)

Year Citation Altmetrics Link
2017 Martin JH, 'Pharmacology', Geriatric Medicine: A Problem-Based Approach 43-57 (2017)
DOI 10.1007/978-981-10-3253-0_4
2016 Martin JH, 'Issues of Pharmacogenomics in Monitoring Warfarin Therapy', Clinical Challenges in Therapeutic Drug Monitoring, Elsevier, Netherlands 261-270 (2016) [B1]
2012 Martin JH, Somogyi A, 'Pharmacogenomics and Warfarin Therapy', Therapeutic Drug Monitoring: Newer Drugs and Biomarkers, Elsevier, Amsterdam, Netherlands 161-174 (2012)
DOI 10.1016/B978-0-12-385467-4.00008-7
2007 Krum H, Martin J, 'Novel Drug Treatments for Hypertension', Comprehensive Hypertension 1049-1060 (2007)
DOI 10.1016/B978-0-323-03961-1.50088-X
2007 Martin JH, 'Contraception', Therapeutic Guidelines 2007, Therapeutic Guidelines 2007, . . (2007)
2007 Martin JH, Krum H, 'Statin therapy in the prevention and treatment of heart failure', The Year In Heart Failure, Clinical Publishing, Atlas Medical Publishing, UK . (2007)
2007 Martin JH, 'Getting to know your drugs', Therapeutic Guidelines, Therapeutic Guidelines 2007 Endocrinology Group, . 161-174 (2007)
2007 Martin JH, Krum H, Gilbert R, 'Interactions between antihypertensive drugs and other medications', Comprehensive hypertension, Elsevier, New York (2007)
2006 Martin JH, 'Cardiovascular Drugs', Australian Medicines Handbook (7th Ed), Australian Medicines Handbook, Melbourne . (2006)
2003 Martin JH, Sim M, Hulse G, 'Opioids', Alcohol and Drug Problems- A Case Studies Workbook, Oxford University Press, South Melbourne 1-34 (2003)
2003 Martin JH, Liew D, Johnson S, 'Benzodiazepines', Alcohol and Drug Problems - A Case Studies Workbook, Oxford University Press, South Melbourne 132-157 (2003)
2003 Martin JH, Johnson S, Liew D, 'Cannabis, Hallucucinogens and CNS Stimulants', Alcohol and Drug Problems - A Case Studies Workbook, Oxford University Press, South Melbourne 61-97 (2003)
Co-authors Amanda Baker
2002 Martin JH, Krum H, Haas S, Gilbert R, 'Metabolic co-morbid conditions in heart failure: Diabetes and hypercholesterolemia', Heart Failure Annual, Heart Failure Annual, London 35-58 (2002)
2002 Martin JH, Cape G, Hulse G, Robinson G, McLean S, Saunders J, Young R, 'Sedative-Hypnotics', Management of alcohol and drug problems, Oxford University Press, Adelaide 212-227 (2002)
2002 Martin JH, Todd F, McLean S, Krum H, Copeland J, 'Cannabis', Management of alcohol and drug problems, Oxford University Press, Adelaide 141-157 (2002)
2002 Martin JH, White J, Krum H, McLean S, Young R, Saunders J, 'Hallucinogens', Management of alcohol and drug problems, Oxford University Press, Adelaide 229-238 (2002)
2002 Martin JH, Young R, Saunders J, Hulse G, McLean S, Robinson G, 'Opiods', Management of alcohol and drug problems, Oxford University Press, Adelaide 79-99 (2002)
Show 14 more chapters

Journal article (208 outputs)

Year Citation Altmetrics Link
2018 Solowij N, Galettis P, Broyd SJ, de Krey P, Martin JH, 'Second-Hand Exposure of Staff Administering Vaporised Cannabinoid Products to Patients in a Hospital Setting', Drugs in R and D, 18 41-44 (2018) [C1]

© 2018, The Author(s). Background: In many health settings, administration of medicinal cannabis poses significant implementation barriers including drug storage and safety for ad... [more]

© 2018, The Author(s). Background: In many health settings, administration of medicinal cannabis poses significant implementation barriers including drug storage and safety for administering staff and surrounding patients. Different modes of administration also provide different yet potentially significant issues. One route that has become of clinical interest owing to the rapid onset of action and patient control of the inhaled amount (via breath timing and depth) is that of vaporisation of cannabinoid products. Although requiring a registered therapeutic device for administration, this is a relatively safe method of intrapulmonary administration that may be particularly useful for patients with difficulty swallowing, and for those in whom higher concentrations of cannabinoids are needed quickly. A particular concern expressed to researchers undertaking clinical trials in the hospital is that other patients, nurses, and clinical or research staff may be exposed to second-hand vapours in the course of administering vaporised products to patients. Objective: The objective of this study was to take samples from two research staff involved in administering vaporised ¿ 9 -tetrahydrocannabinol to participants in a clinical trial, to examine and quantitate cannabinoid presence. Methods: Blood samples from two research staff were taken during the exposure period for three participants (cannabis users) over the course of approximately 2.5¿h and analysed using tandem mass spectrometry. Results: Blood samples taken over a vaporised period revealed exposure below the limit of detection for ¿ 9 -tetrahydrocannabinol and two metabolites, using tandem mass spectrometry analytical methods. Conclusions: These results are reassuring for hospital and clinical trial practices with staff administering vaporised cannabinoid products, and helpful to ethics committees wishing to quantify risk.

DOI 10.1007/s40268-017-0225-5
Co-authors Peter Galettis
2018 Martin JH, Bonomo Y, Reynolds AD, 'Compassion and evidence in prescribing cannabinoids: a perspective from the Royal Australasian College of Physicians.', The Medical journal of Australia, 208 107-109 (2018) [C1]
2018 Bernardes CM, Martin J, Cole P, Kitchener T, Cowburn G, Garvey G, et al., 'Lessons learned from a pilot study of an Indigenous patient navigator intervention in Queensland, Australia', European Journal of Cancer Care, 27 (2018) [C1]
DOI 10.1111/ecc.12714
Citations Scopus - 1
2018 He W, Martin JH, Shaw PN, Lu X, Walpole ET, Dimeski G, 'A Simple and Sensitive LC-MS/MS Method for the Simultaneous Determination of Cyclophosphamide and Dexorubicin Concentrations in Human Plasma', CURRENT PHARMACEUTICAL ANALYSIS, 14 53-59 (2018) [C1]
DOI 10.2174/1573412913666170321111815
2018 McGee M, Whitehead N, Martin J, Collins N, 'Drug-associated pulmonary arterial hypertension.', Clin Toxicol (Phila), 1-9 (2018)
DOI 10.1080/15563650.2018.1447119
2018 Martin JH, Schneider J, Lucas CJ, Galettis P, 'Author Correction: Exogenous Cannabinoid Efficacy: Merely a Pharmacokinetic Interaction?', Clin Pharmacokinet, (2018)
DOI 10.1007/s40262-018-0633-x
Co-authors Jennifer Schneider, Peter Galettis
2018 Solowij N, Broyd SJ, Beale C, Prick J-A, Greenwood L-M, van Hell H, et al., 'Therapeutic Effects of Prolonged Cannabidiol Treatment on Psychological Symptoms and Cognitive Function in Regular Cannabis Users: A Pragmatic Open-Label Clinical Trial.', Cannabis Cannabinoid Res, 3 21-34 (2018) [C1]
DOI 10.1089/can.2017.0043
Co-authors Peter Galettis
2018 Tam L, Garvey G, Meiklejohn J, Martin J, Adams J, Walpole E, et al., 'Exploring positive survivorship experiences of indigenous Australian cancer patients', International Journal of Environmental Research and Public Health, 15 (2018) [C1]
DOI 10.3390/ijerph15010135
Co-authors Michael Fay
2018 Lucas CJ, Galettis P, Song S, Solowij N, Reuter SE, Schneider J, Martin JH, 'Cannabinoid Disposition After Human Intraperitoneal Use: An Insight Into Intraperitoneal Pharmacokinetic Properties in Metastatic Cancer', Clinical Therapeutics, (2018)

© 2018 Elsevier HS Journals, Inc. Background: Medicinal cannabis is prescribed under the provision of a controlled drug in the Australian Poisons Standard. However, multiple laws ... [more]

© 2018 Elsevier HS Journals, Inc. Background: Medicinal cannabis is prescribed under the provision of a controlled drug in the Australian Poisons Standard. However, multiple laws must be navigated in order for patients to obtain access and imported products can be expensive. Dose-response information for both efficacy and toxicity pertaining to medicinal cannabis is lacking. The pharmacokinetic properties of cannabis administered by traditional routes has been described but to date, there is no literature on the pharmacokinetic properties of an intraperitoneal cannabinoid emulsion. Case description: A cachectic 56-year-old female with stage IV ovarian cancer and peritoneal metastases presented to hospital with fevers, abdominal distension and severe pain, vomiting, anorexia, dehydration and confusion. The patient reported receiving an intraperitoneal injection, purported to contain 12 g of mixed cannabinoid (administered by a deregistered medical practitioner) two days prior to presentation. Additionally, cannabis oil oral capsules were administered in the hours prior to hospital admission. Results: THC concentrations were consistent with the clinical state but not with the known pharmacokinetic properties of cannabis nor of intraperitoneal absorption. THC concentrations at the time of presentation were predicted to be ~60 ng/mL. Evidence suggests that blood THC concentrations > 5 ng/mL are associated with substantial cognitive and psychomotor impairment. The predicted time for concentrations to drop < 5 ng/mL was 49 days after administration. Discussion: The unusual pharmacokinetic properties of the case suggest that there is a large amount unknown about cannabis pharmacokinetic properties. The pharmacokinetic properties of a large amount of a lipid soluble compound given intraperitoneally gave insights into the absorption and distribution of cannabinoids, particularly in the setting of metastatic malignancy.

DOI 10.1016/j.clinthera.2017.12.008
Co-authors Peter Galettis, Jennifer Schneider
2018 Dimmitt SB, Stampfer HG, Martin JH, Warren JB, 'Clinical benefits of evolocumab appear less than hoped', LANCET, 391 933-934 (2018)
2017 Lucas CJ, Patel J, Martin JH, 'Predicting drug interactions in addiction treatment', Internal Medicine Journal, 47 872-878 (2017) [C1]

© 2017 Royal Australasian College of Physicians It is not uncommon to be treating people with addiction who also have significant other health problems, including heart, renal or ... [more]

© 2017 Royal Australasian College of Physicians It is not uncommon to be treating people with addiction who also have significant other health problems, including heart, renal or liver failure, diabetes and vascular disease. These conditions require regular medications to be taken. This can be a problem for people living with addiction and difficult social circumstances affecting compliance, among other issues. Our perspective provides a summary of general pharmacological factors affecting medicine taking in people with addiction problems, to provide a guide for hospital doctors in this setting.

DOI 10.1111/imj.13500
2017 Valery PC, Clark PJ, McPhail SM, Rahman T, Hayward K, Martin J, et al., 'Exploratory study into the unmet supportive needs of people diagnosed with cirrhosis in Queensland, Australia', INTERNAL MEDICINE JOURNAL, 47 429-435 (2017) [C1]
DOI 10.1111/imj.13380
2017 Martin JH, Schneider J, Lucas CJ, Galettis P, 'Exogenous Cannabinoid Efficacy: Merely a Pharmacokinetic Interaction?', Clinical Pharmacokinetics, 1-7 (2017)

© 2017 Springer International Publishing AG Endocannabinoid pharmacology is now relatively well understood with a number of endocannabinoids and endogenous cannabinoid neurotransm... [more]

© 2017 Springer International Publishing AG Endocannabinoid pharmacology is now relatively well understood with a number of endocannabinoids and endogenous cannabinoid neurotransmitters identified and the pharmacokinetics relatively well ascertained. Further, the cannabinoid receptors are now molecularly and pharmacologically characterised and the cell processes involved in endocannabinoid transcription, synthesis, post-translational modification and protein expression are reported. Endogenous cannabinoids have been shown to have key roles in immune and pain pathways and neuro-behavioural signalling including appetite regulation. Significant recent interest has thus been shown in understanding these pathways to guide the development of agents that inhibit the natural catabolism of endogenous cannabinoids to modify pain and appetite, and to synthesise antagonists for the treatment of disease such as obesity. This research is concurrent with the renewed clinical interest in exogenous cannabinoids and their use in disease. However, the complex pharmacology and physiological effects of exogenous cannabinoids, either as individual components or in combination, as extracts or via administration of the whole plant in humans, are less well known. Yet as with all other therapeutics, including those derived from plants, knowledge of the pharmacokinetics and dynamics of the complete plant, the individual chemical molecules and their synthetic versions, including formulations and excipients is a standard part of drug development. This article covers the key pharmacological knowledge required to guide further exploration of the toxicity and efficacy of different cannabinoids and their formulations in blinded placebo-controlled studies.

DOI 10.1007/s40262-017-0599-0
Citations Scopus - 1
Co-authors Peter Galettis, Jennifer Schneider
2017 Meiklejohn JA, Garvey G, Bailie R, Walpole E, Adams J, Williamson D, et al., 'Follow-up cancer care: perspectives of Aboriginal and Torres Strait Islander cancer survivors', Supportive Care in Cancer, 25 1597-1605 (2017) [C1]

© 2017, Springer-Verlag Berlin Heidelberg. Purpose: The purpose of this study was to explore Indigenous Australian cancer survivors¿ perspectives of follow-up cancer care and mana... [more]

© 2017, Springer-Verlag Berlin Heidelberg. Purpose: The purpose of this study was to explore Indigenous Australian cancer survivors¿ perspectives of follow-up cancer care and management. Methods: This is a qualitative study employing individual interviews with 21 Indigenous cancer survivors (13 females, 8 males) recruited from a rural primary health service and large tertiary hospital in Brisbane, Queensland. Yarning methods were used to conduct semi-structured interviews. Yarning is a culturally appropriate, informal conversational process emphasising the importance of storytelling. Results: Findings describe a range of ways in which follow-up cancer care is experienced with four major categories elucidated, namely: links to tertiary health services, links to primary health services, communication between tertiary and primary health services, and lost in transition. Both positive and negative experiences were described; however, the importance of timely and informative discharge information, continuity of care, good communication between tertiary and primary health services, and strong therapeutic relationships were salient issues raised by participants. Conclusions: These findings highlight the importance of establishing strong therapeutic relationships between patients and tertiary and primary health professionals. Also important for survivorship is provision of discharge summaries or care plans at discharge for survivors and general practitioners as well as access to a range of allied health services. Alternative means for follow-up could be investigated for regional and rural survivors to facilitate convenient and cost-effective follow-up care. Finally, provision of responsive and flexible follow-up care to cater for the diverse range of needs and preferences of cancer survivors is required. A patient navigator available across the cancer continuum could go some way to addressing this.

DOI 10.1007/s00520-016-3563-x
Citations Scopus - 1Web of Science - 1
2017 Hayward KL, Horsfall LU, Ruffin BJ, Cottrell WN, Chachay VS, Irvine KM, et al., 'Optimising care of patients with chronic disease: patient-oriented education may improve disease knowledge and self-management', Internal Medicine Journal, 47 952-955 (2017) [C1]
DOI 10.1111/imj.13505
Citations Scopus - 1Web of Science - 1
2017 Dimmitt SB, Martin JH, 'Lipid and other management to improve arterial disease and survival in end stage renal disease', Expert Opinion on Pharmacotherapy, 18 343-349 (2017) [C1]

© 2017 Informa UK Limited, trading as Taylor &amp; Francis Group. Introduction: Arterial disease is common in advancing renal failure, culminating in myocardial infarction with ... [more]

© 2017 Informa UK Limited, trading as Taylor & Francis Group. Introduction: Arterial disease is common in advancing renal failure, culminating in myocardial infarction with cardiac failure, strokes and peripheral and renal artery disease. Attention to cardiac and arterial disease may slow deterioration of renal function. Management of risk factors can reduce these sequelae. Areas covered: Modifiable risk factors for arterial disease and relevant pharmacotherapies. Expert opinion: Cardiovascular disease is the biggest killer in renal failure. Statins are viewed as essential in symptomatic coronary disease and have been shown in non-renal patients to improve survival after myocardial infarction. Cochrane recommends statins in renal failure but not in end stage renal disease or transplant patients. Large well powered clinical trials focussed specifically on renal patients failed to demonstrate cardiovascular outcome or mortality benefits of statins when compared to placebo. Other lipid lowering pharmacotherapies are weaker and adverse effects may account for the absence of net clinical benefit in non-renal patients in published clinical trials. Patients should be started on a statin after myocardial infarction, regardless of lipid levels, but the risk of adverse effects in advanced renal failure with its comorbidities predicates employing only essential doses. Optimal antihypertensive and antithrombotic pharmacotherapy are also priorities.

DOI 10.1080/14656566.2017.1285905
Citations Scopus - 1Web of Science - 1
2017 Hollingworth SA, Ostino R, David MC, Martin JH, Tett SE, 'Ezetimibe: Use, costs, and adverse events in Australia', Cardiovascular Therapeutics, 35 40-46 (2017) [C1]
DOI 10.1111/1755-5922.12236
2017 Head RJ, Fay MF, Cosgrove L, Y C Fung K, Rundle-Thiele D, Martin JH, 'Persistence of DNA adducts, hypermutation and acquisition of cellular resistance to alkylating agents in glioblastoma', Cancer Biology and Therapy, 18 917-926 (2017) [C1]

© 2017 Taylor &amp; Francis Group, LLC. Glioblastoma is a lethal form of brain tumour usually treated by surgical resection followed by radiotherapy and an alkylating chemothera... [more]

© 2017 Taylor & Francis Group, LLC. Glioblastoma is a lethal form of brain tumour usually treated by surgical resection followed by radiotherapy and an alkylating chemotherapeutic agent. Key to the success of this multimodal approach is maintaining apoptotic sensitivity of tumour cells to the alkylating agent. This initial treatment likely establishes conditions contributing to development of drug resistance as alkylating agents form the O 6 -methylguanine adduct. This activates the mismatch repair (MMR) process inducing apoptosis and mutagenesis. This review describes key juxtaposed drivers in the balance between alkylation induced mutagenesis and apoptosis. Mutations in MMR genes are the probable drivers for alkylation based drug resistance. Critical to this interaction are the dose-response and temporal interactions between adduct formation and MMR mutations. The precision in dose interval, dose-responses and temporal relationships dictate a role for alkylating agents in either promoting experimental tumour formation or inducing tumour cell death with chemotherapy. Importantly, this resultant loss of chemotherapeutic selective pressure provides opportunity to explore novel therapeutics and appropriate combinations to minimise alkylation based drug resistance and tumour relapse.

DOI 10.1080/15384047.2017.1385680
Co-authors Michael Fay
2017 de Witt A, Cunningham FC, Bailie R, Bernardes CM, Matthews V, Arley B, et al., 'Identification of Australian Aboriginal and Torres Strait Islander Cancer Patients in the Primary Health Care Setting', FRONTIERS IN PUBLIC HEALTH, 5 1-8 (2017) [C1]
DOI 10.3389/fpubh.2017.00199
2017 Hayward KL, Valery PC, Martin JH, Karmakar A, Patel PJ, Horsfall LU, et al., 'Medication beliefs predict medication adherence in ambulatory patients with decompensated cirrhosis', World Journal of Gastroenterology, 23 7321-7331 (2017) [C1]

© 2017 Baishideng Publishing Group Inc. All rights reserved. Aim: To investigate the impact of medication beliefs, illness perceptions and quality of life on medication adherence ... [more]

© 2017 Baishideng Publishing Group Inc. All rights reserved. Aim: To investigate the impact of medication beliefs, illness perceptions and quality of life on medication adherence in people with decompensated cirrhosis. Methods: One hundred adults with decompensated cirrhosis completed a structured questionnaire when they attended for routine outpatient hepatology review. Measures of self-reported medication adherence (Morisky Medication Adherence Scale), beliefs surrounding medications (Beliefs about Medicines Questionnaire), perceptions of illness and medicines (Brief Illness Perception Questionnaire), and quality of life (Chronic Liver Disease Questionnaire) were examined. Clinical data were obtained via patient history and review of medical records. Least absolute shrinkage and selection operator and stepwise backwards regression techniques were used to construct the multivariable logistic regression model. Statistical significance was set at alpha = 0.05. Results: Medicat ion adherence was "High" in 42% of participants, "Medium" in 37%, and "Low" in 21%. Compared to patients with "High" adherence, those with "Medium" or "Low" adherence were more likely to report difficulty affording their medications (P < 0.001), lower perception of treatment helpfulness (P = 0.003) and stronger medication concerns relative to medication necessity beliefs (P = 0.003). People with "Low" adherence also experienced greater symptom burden and poorer quality of life, including more frequent abdominal pain (P = 0.023), shortness of breath (P = 0.030), and emotional disturbances (P = 0.050). Multivariable analysis identified having stronger medication concerns relative to necessity beliefs (Necessity-Concerns Differential = 5, OR = 3.66, 95%CI: 1.18-11.40) and more frequent shortness of breath (shortness of breath score = 3, OR = 3.87, 95%CI: 1.22-12.25) as independent predictors of "Low" adherence. Conclusion: The association between "Low" adherence and patients having strong concerns or doubting the necessity or helpfulness of their medications should be explored further given the clinical relevance.

DOI 10.3748/wjg.v23.i40.7321
2017 Hayward KL, Martin JH, Cottrell WN, Karmakar A, Horsfall LU, Patel PJ, et al., 'Patient-oriented education and medication management intervention for people with decompensated cirrhosis: Study protocol for a randomized controlled trial', Trials, 18 1-13 (2017) [C1]
DOI 10.1186/s13063-017-2075-4
2017 Patel J, Martin JH, Lucas CJ, 'Comment on a paper by Dupoiron etal. "A phase III randomized controlled study on the efficacy and improved bowel function of prolonged-release (PR) oxycodone- naloxone (up to 160/80mg daily) versus oxycodone PR"', EUROPEAN JOURNAL OF PAIN, 21 1772-1773 (2017)
DOI 10.1002/ejp.1098
2017 Dimmitt SB, Stampfer HG, Martin JH, 'Safety and efficacy of statins', LANCET, 389 1098-1098 (2017)
2017 Williams M, Martin J, Galettis P, 'A validated method for the detection of 32 bath salts in oral fluid', Journal of Analytical Toxicology, 41 659-669 (2017) [C1]

© The Author 2017. Published by Oxford University Press. All rights reserved. Workplace drug testing in Australia is usually adherent to one of two standards, AS/NZS 4308:2008 for... [more]

© The Author 2017. Published by Oxford University Press. All rights reserved. Workplace drug testing in Australia is usually adherent to one of two standards, AS/NZS 4308:2008 for urine or AS 4760:2006 for oral fluid. These standards prescribe the drugs tested, devices used and testing methodology followed by the testing agency. However, they are not comprehensive and for many years workers have been able to consume novel psychoactive substances to avoid detection and without consequences. Here, we present a validated method for the detection of 32 Synthetic Stimulant and Hallucogenic drugs, commonly sold as bath salts, in oral fluid. These drugs are cathinone, ephedrone, methylone, flephedrone, MDA, PMA, methedrone, TMA, MDMA, butylone, mephedrone, MDEA, MEC, pentedrone, MBDB, MTA, Alpha-PVP, MPBP, 2C-B, MDPV, DOB, 2C-T-2, TFMPP, DOET, 2C-T-7, naphyrone, MDAI, FMA, DMA, 25C-NBOMe, 25B-NBOMe and 25T4-NBOMe. Sample preparation was undertaken using a simple protein precipitation in acetonitrile. Chromatographic separation was achieved in 7.5 min on a Kinetex F5 column (50mm × 3mm × 2.6 µm) using 0.1% formic acid in water and acetonitrile as the mobile phases. The method was validated with limit of detection (1 ng/mL), limit of quantitation (2.5 ng/mL), selectivity, linearity (2.5-500 ng/mL), accuracy (85.3-108.4% of the target concentration) and precision (1.9-14%). This method was applied to 12 samples previously submitted for routine testing and two were found to contain 2-CB and DOB (5 and 4 ng/mL) and, MPBP and TFMPP (both at 4 ng/mL). This method provides for the rapid detection of a large number of compounds in oral fluid which is readily applicable to routine testing laboratories.

DOI 10.1093/jat/bkx055
Co-authors Peter Galettis
2017 He W, Martin JH, Shaw PN, Walpole ET, Dimeski G, 'The development of a rapid, simple and sensitive LC-MS/MS method, to guide clinical dosing, for the analysis of 5-fluorouracil in human plasma', Current Pharmaceutical Analysis, 13 378-383 (2017)

© 2017, Bentham Science Publishers. Introduction: 5-Fluorouracil is a commonly prescribed antineoplastic drug. Historically, methods to determine this compound in biological fluid... [more]

© 2017, Bentham Science Publishers. Introduction: 5-Fluorouracil is a commonly prescribed antineoplastic drug. Historically, methods to determine this compound in biological fluids have been time consuming or not sensitive enough. Materials and Methods: In this report, a method using simple and rapid sample preparation with good sensitivity, precision and accuracy for the quantitative determination of 5-fluorouracil in human plasma by LC-MS/MS is established and validated. By the judicious combination of a small amount of injected sample, low flow rate, careful control of gradient elution profile, use of a HILIC pre-column to further remove residual phospholipids and an isotopically labelled internal standard (ILIS), the method has successfully overcome matrix effect with protein precipitation sample pre-treatment without evaporating to dryness and reconstituting process. Conclusion: This newly developed method can be used to measure patient plasma concentrations of 5- fluorouracil, as low as 0.8 ng/mL and as high as 100 µg/mL, with less than 15% both intra- and interday accuracy and precision. Such a methodology will be very convenient of being used in routine therapeutic drug monitoring.

DOI 10.2174/1573412912666160811114339
Citations Scopus - 1
2017 Matz M, Coleman MP, Sant M, Chirlaque MD, Visser O, Gore M, et al., 'The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2)', Gynecologic Oncology, 144 405-413 (2017)

© 2016 Objective Ovarian cancers comprise several histologically distinct tumour groups with widely different prognosis. We aimed to describe the worldwide distribution of ovarian... [more]

© 2016 Objective Ovarian cancers comprise several histologically distinct tumour groups with widely different prognosis. We aimed to describe the worldwide distribution of ovarian cancer histology and to understand what role this may play in international variation in survival. Methods The CONCORD programme is the largest population-based study of global trends in cancer survival. Data on 681,759 women diagnosed during 1995¿2009 with cancer of the ovary, fallopian tube, peritoneum and retroperitonum in 51 countries were included. We categorised ovarian tumours into six histological groups, and explored the worldwide distribution of histology. Results During 2005¿2009, type II epithelial tumours were the most common. The proportion was much higher in Oceania (73.1%), North America (73.0%) and Europe (72.6%) than in Central and South America (65.7%) and Asia (56.1%). By contrast, type I epithelial tumours were more common in Asia (32.5%), compared with only 19.4% in North America. From 1995 to 2009, the proportion of type II epithelial tumours increased from 68.6% to 71.1%, while the proportion of type I epithelial tumours fell from 23.8% to 21.2%. The proportions of germ cell tumours, sex cord-stromal tumours, other specific non-epithelial tumours and tumours of non-specific morphology all remained stable over time. Conclusions The distribution of ovarian cancer histology varies widely worldwide. Type I epithelial, germ cell and sex cord-stromal tumours are generally associated with higher survival than type II tumours, so the proportion of these tumours may influence survival estimates for all ovarian cancers combined. The distribution of histological groups should be considered when comparing survival between countries and regions.

DOI 10.1016/j.ygyno.2016.10.019
Citations Scopus - 1
2017 Valery PC, Clark PJ, McPhail SM, Rahman T, Hayward K, Martin J, et al., 'Exploratory study into the unmet supportive needs of people diagnosed with cirrhosis in Queensland, Australia', INTERNAL MEDICINE JOURNAL, 47 429-435 (2017)
DOI 10.1111/imj.13380
2017 Donagher J, Martin JH, Barras MA, 'Individualised medicine: why we need Bayesian dosing.', Intern Med J, 47 593-600 (2017) [C1]
DOI 10.1111/imj.13412
2017 Dimmitt S, Stampfer H, Martin JH, 'When less is more ¿ efficacy with less toxicity at the ED50', British Journal of Clinical Pharmacology, 83 1365-1368 (2017) [C1]
DOI 10.1111/bcp.13281
2017 Matz M, Coleman MP, Carreira H, Salmerón D, Chirlaque MD, Allemani C, et al., 'Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)', Gynecologic Oncology, 144 396-404 (2017) [C1]

© 2016 Elsevier Inc. Objective Ovarian cancer comprises several histological groups with widely differing levels of survival. We aimed to explore international variation in surviv... [more]

© 2016 Elsevier Inc. Objective Ovarian cancer comprises several histological groups with widely differing levels of survival. We aimed to explore international variation in survival for each group to help interpret international differences in survival from all ovarian cancers combined. We also examined differences in stage-specific survival. Methods The CONCORD programme is the largest population-based study of global trends in cancer survival, including data from 60 countries for 695,932 women (aged 15¿99¿years) diagnosed with ovarian cancer during 1995¿2009. We defined six histological groups: type I epithelial, type II epithelial, germ cell, sex cord-stromal, other specific non-epithelial and non-specific morphology, and estimated age-standardised 5-year net survival for each country by histological group. We also analysed data from 67 cancer registries for 233,659 women diagnosed from 2001 to 2009, for whom information on stage at diagnosis was available. We estimated age-standardised 5-year net survival by stage at diagnosis (localised or advanced). Results Survival from type I epithelial ovarian tumours for women diagnosed during 2005¿09 ranged from 40 to 70%. Survival from type II epithelial tumours was much lower (20¿45%). Survival from germ cell tumours was higher than that of type II epithelial tumours, but also varied widely between countries. Survival for sex-cord stromal tumours was higher than for the five other groups. Survival from localised tumours was much higher than for advanced disease (80% vs. 30%). Conclusions There is wide variation in survival between histological groups, and stage at diagnosis remains an important factor in ovarian cancer survival. International comparisons of ovarian cancer survival should incorporate histology.

DOI 10.1016/j.ygyno.2016.11.019
Citations Scopus - 8
2017 Matz M, Coleman MP, Sant M, Chirlaque MD, Visser O, Gore M, et al., 'The histology of ovarian cancer: worldwide distribution and implications for international survival comparisons (CONCORD-2)', Gynecologic Oncology, 144 405-413 (2017) [C1]

© 2016 Objective Ovarian cancers comprise several histologically distinct tumour groups with widely different prognosis. We aimed to describe the worldwide distribution of ovarian... [more]

© 2016 Objective Ovarian cancers comprise several histologically distinct tumour groups with widely different prognosis. We aimed to describe the worldwide distribution of ovarian cancer histology and to understand what role this may play in international variation in survival. Methods The CONCORD programme is the largest population-based study of global trends in cancer survival. Data on 681,759 women diagnosed during 1995¿2009 with cancer of the ovary, fallopian tube, peritoneum and retroperitonum in 51 countries were included. We categorised ovarian tumours into six histological groups, and explored the worldwide distribution of histology. Results During 2005¿2009, type II epithelial tumours were the most common. The proportion was much higher in Oceania (73.1%), North America (73.0%) and Europe (72.6%) than in Central and South America (65.7%) and Asia (56.1%). By contrast, type I epithelial tumours were more common in Asia (32.5%), compared with only 19.4% in North America. From 1995 to 2009, the proportion of type II epithelial tumours increased from 68.6% to 71.1%, while the proportion of type I epithelial tumours fell from 23.8% to 21.2%. The proportions of germ cell tumours, sex cord-stromal tumours, other specific non-epithelial tumours and tumours of non-specific morphology all remained stable over time. Conclusions The distribution of ovarian cancer histology varies widely worldwide. Type I epithelial, germ cell and sex cord-stromal tumours are generally associated with higher survival than type II tumours, so the proportion of these tumours may influence survival estimates for all ovarian cancers combined. The distribution of histological groups should be considered when comparing survival between countries and regions.

DOI 10.1016/j.ygyno.2016.10.019
Citations Scopus - 4
2017 Bonaventure A, Harewood R, Stiller CA, Gatta G, Clavel J, Stefan DC, et al., 'Worldwide comparison of survival from childhood leukaemia for 1995¿2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89¿828 children from 198 registries in 53 countries', The Lancet Haematology, 4 e202-e217 (2017) [C1]

© 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Background Global inequalities in access to health care are reflected in di... [more]

© 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Background Global inequalities in access to health care are reflected in differences in cancer survival. The CONCORD programme was designed to assess worldwide differences and trends in population-based cancer survival. In this population-based study, we aimed to estimate survival inequalities globally for several subtypes of childhood leukaemia. Methods Cancer registries participating in CONCORD were asked to submit tumour registrations for all children aged 0¿14 years who were diagnosed with leukaemia between Jan 1, 1995, and Dec 31, 2009, and followed up until Dec 31, 2009. Haematological malignancies were defined by morphology codes in the International Classification of Diseases for Oncology, third revision. We excluded data from registries from which the data were judged to be less reliable, or included only lymphomas, and data from countries in which data for fewer than ten children were available for analysis. We also excluded records because of a missing date of birth, diagnosis, or last known vital status. We estimated 5-year net survival (ie, the probability of surviving at least 5 years after diagnosis, after controlling for deaths from other causes [background mortality]) for children by calendar period of diagnosis (1995¿99, 2000¿04, and 2005¿09), sex, and age at diagnosis ( < 1, 1¿4, 5¿9, and 10¿14 years, inclusive) using appropriate life tables. We estimated age-standardised net survival for international comparison of survival trends for precursor-cell acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). Findings We analysed data from 89¿828 children from 198 registries in 53 countries. During 1995¿99, 5-year age-standardised net survival for all lymphoid leukaemias combined ranged from 10·6% (95% CI 3·1¿18·2) in the Chinese registries to 86·8% (81·6¿92·0) in Austria. International differences in 5-year survival for childhood leukaemia were still large as recently as 2005¿09, when age-standardised survival for lymphoid leukaemias ranged from 52·4% (95% CI 42·8¿61·9) in Cali, Colombia, to 91·6% (89·5¿93·6) in the German registries, and for AML ranged from 33·3% (18·9¿47·7) in Bulgaria to 78·2% (72·0¿84·3) in German registries. Survival from precursor-cell ALL was very close to that of all lymphoid leukaemias combined, with similar variation. In most countries, survival from AML improved more than survival from ALL between 2000¿04 and 2005¿09. Survival for each type of leukaemia varied markedly with age: survival was highest for children aged 1¿4 and 5¿9 years, and lowest for infants (younger than 1 year). There was no systematic difference in survival between boys and girls. Interpretation Global inequalities in survival from childhood leukaemia have narrowed with time but remain very wide for both ALL and AML. These results provide useful information for health policy makers on the effectiveness of health-care systems and for cancer policy makers to reduce inequalities in childhood cancer survival. Funding Canadian Partnership Against Cancer, Cancer Focus Northern Ireland, Cancer Institute New South Wales, Cancer Research UK, US Centers for Disease Control and Prevention, Swiss Re, Swiss Cancer Research foundation, Swiss Cancer League, and the University of Kentucky.

DOI 10.1016/S2352-3026(17)30052-2
Citations Scopus - 17
2017 Matz M, Coleman MP, Carreira H, Salmerón D, Chirlaque MD, Allemani C, et al., 'Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2)', Gynecologic Oncology, 144 396-404 (2017)

© 2016 Elsevier Inc. Objective Ovarian cancer comprises several histological groups with widely differing levels of survival. We aimed to explore international variation in surviv... [more]

© 2016 Elsevier Inc. Objective Ovarian cancer comprises several histological groups with widely differing levels of survival. We aimed to explore international variation in survival for each group to help interpret international differences in survival from all ovarian cancers combined. We also examined differences in stage-specific survival. Methods The CONCORD programme is the largest population-based study of global trends in cancer survival, including data from 60 countries for 695,932 women (aged 15¿99¿years) diagnosed with ovarian cancer during 1995¿2009. We defined six histological groups: type I epithelial, type II epithelial, germ cell, sex cord-stromal, other specific non-epithelial and non-specific morphology, and estimated age-standardised 5-year net survival for each country by histological group. We also analysed data from 67 cancer registries for 233,659 women diagnosed from 2001 to 2009, for whom information on stage at diagnosis was available. We estimated age-standardised 5-year net survival by stage at diagnosis (localised or advanced). Results Survival from type I epithelial ovarian tumours for women diagnosed during 2005¿09 ranged from 40 to 70%. Survival from type II epithelial tumours was much lower (20¿45%). Survival from germ cell tumours was higher than that of type II epithelial tumours, but also varied widely between countries. Survival for sex-cord stromal tumours was higher than for the five other groups. Survival from localised tumours was much higher than for advanced disease (80% vs. 30%). Conclusions There is wide variation in survival between histological groups, and stage at diagnosis remains an important factor in ovarian cancer survival. International comparisons of ovarian cancer survival should incorporate histology.

DOI 10.1016/j.ygyno.2016.11.019
Citations Scopus - 6
2017 Valery PC, Clark PJ, McPhail SM, Rahman T, Hayward K, Martin J, et al., 'Exploratory study into the unmet supportive needs of people diagnosed with cirrhosis in Queensland, Australia', INTERNAL MEDICINE JOURNAL, 47 429-435 (2017) [C1]
DOI 10.1111/imj.13380
2017 Nicoletti P, Aithal GP, Bjornsson ES, Andrade RJ, Sawle A, Arrese M, et al., 'Association of Liver Injury From Specific Drugs, or Groups of¿Drugs, With Polymorphisms in HLA and Other Genes in a¿Genome-Wide Association Study', Gastroenterology, 152 1078-1089 (2017) [C1]
DOI 10.1053/j.gastro.2016.12.016
Citations Scopus - 17Web of Science - 10
2017 Kim HY, Martin JH, Mclachlan AJ, Boddy AV, 'Precision dosing of targeted anticancer drugs-challenges in the real world', Translational Cancer Research, 6 S1500-S1511 (2017) [C1]

© Translational Cancer Research. The prerequisites for the successful implementation of therapeutic drug monitoring (TDM) include high inter-subject variation, low inter-occasion ... [more]

© Translational Cancer Research. The prerequisites for the successful implementation of therapeutic drug monitoring (TDM) include high inter-subject variation, low inter-occasion variation, narrow therapeutic index and a strong link between plasma drug concentrations and clinical effects. The degree to which targeted anticancer drugs meet these criteria is not the only consideration in implementing precision dosing. Methodological, logistical, funding and cultural barriers also provide challenges to the successful implementation of approaches to individualised therapy. This review considers the barriers to the routine use of TDM, using examples from both conventional (cytotoxic) anticancer, but also considering more recent data and examples more relevant to chronic, oral administration of targeted therapies. Based on these examples and the associated principles for the implementation of precision dosing, proposals may be made for a more rational, real-world approach to the best use of precision medicines.

DOI 10.21037/tcr.2017.10.30
Citations Scopus - 1Web of Science - 1
2017 Bonaventure A, Harewood R, Stiller CA, Gatta G, Clavel J, Stefan DC, et al., 'Worldwide comparison of survival from childhood leukaemia for 1995¿2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89¿828 children from 198 registries in 53 countries', The Lancet Haematology, 4 e202-e217 (2017)

© 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Background Global inequalities in access to health care are reflected in di... [more]

© 2017 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license Background Global inequalities in access to health care are reflected in differences in cancer survival. The CONCORD programme was designed to assess worldwide differences and trends in population-based cancer survival. In this population-based study, we aimed to estimate survival inequalities globally for several subtypes of childhood leukaemia. Methods Cancer registries participating in CONCORD were asked to submit tumour registrations for all children aged 0¿14 years who were diagnosed with leukaemia between Jan 1, 1995, and Dec 31, 2009, and followed up until Dec 31, 2009. Haematological malignancies were defined by morphology codes in the International Classification of Diseases for Oncology, third revision. We excluded data from registries from which the data were judged to be less reliable, or included only lymphomas, and data from countries in which data for fewer than ten children were available for analysis. We also excluded records because of a missing date of birth, diagnosis, or last known vital status. We estimated 5-year net survival (ie, the probability of surviving at least 5 years after diagnosis, after controlling for deaths from other causes [background mortality]) for children by calendar period of diagnosis (1995¿99, 2000¿04, and 2005¿09), sex, and age at diagnosis ( < 1, 1¿4, 5¿9, and 10¿14 years, inclusive) using appropriate life tables. We estimated age-standardised net survival for international comparison of survival trends for precursor-cell acute lymphoblastic leukaemia (ALL) and acute myeloid leukaemia (AML). Findings We analysed data from 89¿828 children from 198 registries in 53 countries. During 1995¿99, 5-year age-standardised net survival for all lymphoid leukaemias combined ranged from 10·6% (95% CI 3·1¿18·2) in the Chinese registries to 86·8% (81·6¿92·0) in Austria. International differences in 5-year survival for childhood leukaemia were still large as recently as 2005¿09, when age-standardised survival for lymphoid leukaemias ranged from 52·4% (95% CI 42·8¿61·9) in Cali, Colombia, to 91·6% (89·5¿93·6) in the German registries, and for AML ranged from 33·3% (18·9¿47·7) in Bulgaria to 78·2% (72·0¿84·3) in German registries. Survival from precursor-cell ALL was very close to that of all lymphoid leukaemias combined, with similar variation. In most countries, survival from AML improved more than survival from ALL between 2000¿04 and 2005¿09. Survival for each type of leukaemia varied markedly with age: survival was highest for children aged 1¿4 and 5¿9 years, and lowest for infants (younger than 1 year). There was no systematic difference in survival between boys and girls. Interpretation Global inequalities in survival from childhood leukaemia have narrowed with time but remain very wide for both ALL and AML. These results provide useful information for health policy makers on the effectiveness of health-care systems and for cancer policy makers to reduce inequalities in childhood cancer survival. Funding Canadian Partnership Against Cancer, Cancer Focus Northern Ireland, Cancer Institute New South Wales, Cancer Research UK, US Centers for Disease Control and Prevention, Swiss Re, Swiss Cancer Research foundation, Swiss Cancer League, and the University of Kentucky.

DOI 10.1016/S2352-3026(17)30052-2
Citations Scopus - 8
2017 Martin JH, May JA, 'The challenge of discharge: combining medication reconciliation and discharge planning', MEDICAL JOURNAL OF AUSTRALIA, 206 20-+ (2017)
DOI 10.5694/mja16.01157
Co-authors Jennifer May
2017 Mitrev N, Vande Casteele N, Seow CH, Andrews JM, Connor SJ, Moore GT, et al., 'Review article: consensus statements on therapeutic drug monitoring of anti-tumour necrosis factor therapy in inflammatory bowel diseases.', Alimentary pharmacology & therapeutics, 46 137-143 (2017) [C1]
DOI 10.1111/apt.14368
2017 Lucas CJ, Martin JH, 'Pharmacokinetic-Guided Dosing of New Oral Cancer Agents', Journal of Clinical Pharmacology, 57 S78-S98 (2017) [C1]

© 2017, The American College of Clinical Pharmacology Generally, licensed drug-dosing recommendations for chemotherapy are based on results from clinical trials in which subjects ... [more]

© 2017, The American College of Clinical Pharmacology Generally, licensed drug-dosing recommendations for chemotherapy are based on results from clinical trials in which subjects are usually of relatively normal body size, middle-aged, and are relatively racially homogeneous, with minimal comorbidity and specific tumor characteristics. Very few nontrial patients meet these characteristics, resulting in clinical practice having to extrapolate dosing recommendations to the specific patient. There is insufficient research on the impact of obesity-associated physiological changes prevalent in patients with common cancers on standard pharmacokinetic and pharmacodynamic parameters. Yet quantifying the influence of obesity on the pharmacology of chemotherapy is vital, as dosing inappropriate for body composition (ie, flat dosing or mg/kg based on total body weight) may increase the risk of adverse events and reduce clinical effectiveness. Unfortunately, there are few cancer guidelines to aid clinicians in selecting the optimal dose in the obese¿even recent guidelines are based predominantly on clinical opinion/current practice in treating obese patients, rather than evidence. Data in many other vulnerable groups, for example, those with significant comorbidity and older patients, are also scarce. Because of the known limitations of body surface area¿guided dosing, therapeutic drug monitoring or pharmacokinetic-guided dosing, which predicts an individual's exposure, has increasingly been shown to be a powerful tool in cancer therapy. Used appropriately, it can adjust for differences in pharmacokinetic parameters not considered when body size¿based dosing or ¿one dose fits all¿ is used. This review will focus predominantly on the rationale for pharmacokinetic-guided dosing of the newer oral molecularly targeted antineoplastics in people whose drug exposure is not predicted by their physiology or body composition.

DOI 10.1002/jcph.937
Citations Scopus - 1Web of Science - 1
2016 Galettis P, Schneider J, Martin J, 'Care with overseas purchased drugs: devil is in the detail', INTERNAL MEDICINE JOURNAL, 46 1005-1006 (2016)
DOI 10.1111/imj.13184
Co-authors Jennifer Schneider, Peter Galettis
2016 Martin JH, Bonomo YA, 'Medicinal cannabis in Australia: the missing links', MEDICAL JOURNAL OF AUSTRALIA, 204 371-+ (2016)
DOI 10.5694/mja16.00234
Citations Web of Science - 6
2016 Luckett T, Phillips J, Lintzeris N, Allsop D, Lee J, Solowij N, et al., 'Clinical trials of medicinal cannabis for appetite-related symptoms from advanced cancer: a survey of preferences, attitudes and beliefs among patients willing to consider participation', Internal Medicine Journal, 46 1269-1275 (2016) [C1]

© 2016 Royal Australasian College of Physicians Background: Australian clinical trials are planned to evaluate medicinal cannabis in a range of clinical contexts. Aims: To explore... [more]

© 2016 Royal Australasian College of Physicians Background: Australian clinical trials are planned to evaluate medicinal cannabis in a range of clinical contexts. Aims: To explore the preferences, attitudes and beliefs of patients eligible and willing to consider participation in a clinical trial of medicinal cannabis for poor appetite and appetite-related symptoms from advanced cancer. Methods: A cross-sectional anonymous survey was administered from July to December 2015 online and in eight adult outpatient palliative care and/or cancer services. Respondents were eligible if they were =18 years, had advanced cancer and poor appetite/taste problems/weight loss and might consider participating in a medicinal cannabis trial. Survey items focused on medicinal rather than recreational cannabis use and did not specify botanical or pharmaceutical products. Items asked about previous medicinal cannabis use and preferences for delivery route and invited comments and concerns. Results: There were 204 survey respondents, of whom 26 (13%) reported prior medicinal cannabis use. Tablets/capsules were the preferred delivery mode (n = 144, 71%), followed by mouth spray (n = 84, 42%) and vaporiser (n = 83, 41%). Explanations for preferences (n = 134) most commonly cited convenience (n = 66; 49%). A total of 82% (n = 168) of respondents indicated that they had no trial-related concerns, but a small number volunteered concerns about adverse effects (n = 14) or wanted more information/advice (n = 8). Six respondents volunteered a belief that cannabis might cure cancer, while two wanted assurance of efficacy before participating in a trial. Conclusion: Justification of modes other than tablets/capsules and variable understanding about cannabis and trials will need addressing in trial-related information to optimise recruitment and ensure that consent is properly informed.

DOI 10.1111/imj.13224
Citations Scopus - 1Web of Science - 1
2016 Bonomo Y, Zundel S, Martin JH, 'Addressing unconscious bias for female clinical academics', INTERNAL MEDICINE JOURNAL, 46 391-393 (2016)
DOI 10.1111/imj.13022
Citations Scopus - 2Web of Science - 2
2016 Schneider J, Galettis P, Williams M, Lucas C, Martin JH, 'Pill testing at music festivals: can we do more harm?', INTERNAL MEDICINE JOURNAL, 46 1249-1251 (2016)
DOI 10.1111/imj.13250
Citations Scopus - 1Web of Science - 1
Co-authors Peter Galettis, Jennifer Schneider
2016 Skinner TR, Scott IA, Martin JH, 'Diagnostic errors in older patients: A systematic review of incidence and potential causes in seven prevalent diseases', International Journal of General Medicine, 9 137-146 (2016) [C1]

© 2016 Skinner et al. Background: Misdiagnosis, either over-or underdiagnosis, exposes older patients to increased risk of inappropriate or omitted investigations and treatments, ... [more]

© 2016 Skinner et al. Background: Misdiagnosis, either over-or underdiagnosis, exposes older patients to increased risk of inappropriate or omitted investigations and treatments, psychological distress, and financial burden. Objective: To evaluate the frequency and nature of diagnostic errors in 16 conditions prevalent in older patients by undertaking a systematic literature review. Data sources and study selection: Cohort studies, cross-sectional studies, or systematic reviews of such studies published in Medline between September 1993 and May 2014 were searched using key search terms of ¿diagnostic error¿, ¿misdiagnosis¿, ¿accuracy¿, ¿validity¿, or ¿diagnosis¿ and terms relating to each disease. Data synthesis: A total of 938 articles were retrieved. Diagnostic error rates of > 10% for both over-and underdiagnosis were seen in chronic obstructive pulmonary disease, dementia, Parkinson¿s disease, heart failure, stroke/transient ischemic attack, and acute myocardial infarction. Diabetes was overdiagnosed in < 5% of cases. Conclusion: Over-and underdiagnosis are common in older patients. Explanations for overdiagnosis include subjective diagnostic criteria and the use of criteria not validated in older patients. Underdiagnosis was associated with long preclinical phases of disease or lack of sensitive diagnostic criteria. Factors that predispose to misdiagnosis in older patients must be emphasized in education and clinical guidelines.

DOI 10.2147/IJGM.S96741
Citations Scopus - 9Web of Science - 9
2016 Meiklejohn JA, Mimery A, Martin JH, Bailie R, Garvey G, Walpole ET, et al., 'The role of the GP in follow-up cancer care: a systematic literature review', Journal of Cancer Survivorship, 10 990-1011 (2016) [C1]

© 2016, Springer Science+Business Media New York. Purpose: The purpose of the present study is to explore the role of the general practitioners, family physicians and primary care... [more]

© 2016, Springer Science+Business Media New York. Purpose: The purpose of the present study is to explore the role of the general practitioners, family physicians and primary care physicians (GP) in the provision of follow-up cancer care. Methods: PubMed, MEDLINE and CINAHL were systematically searched for primary research focussing on the role of the GP from the perspective of GPs and patients. Data were extracted using a standardised form and synthesised using a qualitative descriptive approach. Results: The initial search generated 6487 articles: 25 quantitative and 33 qualitative articles were included. Articles focused on patients¿ and GPs¿ perspectives of the GP role in follow-up cancer care. Some studies reported on the current role of the GP, barriers and enablers to GP involvement from the perspective of the GP and suggestions for future GP roles. Variations in guidelines and practice of follow-up cancer care in the primary health care sector exist. However, GPs and patients across the included studies supported a greater GP role in follow-up cancer care. This included greater support for care coordination, screening, diagnosis and management of physical and psychological effects of cancer and its treatment, symptom and pain relief, health promotion, palliative care and continuing normal general health care provision. Conclusion: While there are variations in guidelines and practice of follow-up cancer care in the primary health care sector, GPs and patients across the reviewed studies supported a greater role by the GP. Implications for Cancer Survivors: Greater GP role in cancer care could improve the quality of patient care for cancer survivors. Better communication between the tertiary sector and GP across the cancer phases would enable clear delineation of roles.

DOI 10.1007/s11764-016-0545-4
Citations Scopus - 8Web of Science - 8
2016 Lucas C, Byles J, Martin JH, 'Medicines optimisation in older people: Taking age and sex into account', Maturitas, 93 114-120 (2016) [C1]

© 2016 Elsevier Ireland Ltd There are a number of complex and seemingly ignored issues around prescribing safely and effectively for older people, particularly for very old women.... [more]

© 2016 Elsevier Ireland Ltd There are a number of complex and seemingly ignored issues around prescribing safely and effectively for older people, particularly for very old women. These issues include polypharmacy, possible compliance issues and communication barriers between patient, specialists and general practitioners (GPs). There are specific pharmacokinetic (PK) and pharmacodynamic (PD) parameters that change in older age generally, and in women more specifically, which if ignored are likely to cause symptoms and to impair quality of life when drug dosage is unchanged. These changed PK and PD parameters are not all-or-nothing processes, but a continuum across age, sex and comorbidity. Very old people also have less ¿reserve¿ when drugs are used in ¿standard' doses, are more likely to have multiple concurrent therapies, and the risk of adverse effects of drugs in this group is very high. Doctors need to consider these issues when providing therapy for this group, or when trying to unravel the complex prescribing cascade here. This review outlines general principles to consider when prescribing for older people, focusing on age- and sex-related changes in both PK and PD processes.

DOI 10.1016/j.maturitas.2016.06.021
Citations Scopus - 4Web of Science - 4
Co-authors Julie Byles
2016 Meiklejohn JA, Adams J, Valery PC, Walpole ET, Martin JH, Williams HM, Garvey G, 'Health professional's perspectives of the barriers and enablers to cancer care for Indigenous Australians', European Journal of Cancer Care, 25 254-261 (2016) [C1]

© 2016 John Wiley &amp; Sons Ltd. To investigate health professionals&apos; perspectives about factors that impede or facilitate cancer care for Indigenous people. Semi-structur... [more]

© 2016 John Wiley & Sons Ltd. To investigate health professionals' perspectives about factors that impede or facilitate cancer care for Indigenous people. Semi-structured interviews with 22 health professionals involved in Indigenous cancer care. Data were interpreted using an inductive thematic analysis approach. Participants presented their perspectives on a number of barriers and enablers to Indigenous cancer care. Barriers were related to challenges with communication, the health system and coordination of care, issues around individual and community priorities and views of cancer treatment and health professional judgement. Enablers to cancer care were related to the importance of trust and rapport as well as health care system and support factors. The findings highlighted the need for recording of Indigenous status in medical records and a coordinated approach to the provision of evidence-based and culturally appropriate cancer care. This could go some way to improving Indigenous patient's engagement with tertiary cancer care services.

DOI 10.1111/ecc.12467
Citations Scopus - 2Web of Science - 2
2016 Linger MW, van Driel ML, Hollingworth SA, Martin JH, 'Off-label use of tumour necrosis factor-alpha inhibitors and anakinra at an Australian tertiary hospital', Internal Medicine Journal, 46 1386-1391 (2016) [C1]

© 2016 Royal Australasian College of Physicians Background: Tumour necrosis factor-alpha inhibitors (anti-TNFa) and anakinra are monoclonal antibodies against pro-inflammatory cyt... [more]

© 2016 Royal Australasian College of Physicians Background: Tumour necrosis factor-alpha inhibitors (anti-TNFa) and anakinra are monoclonal antibodies against pro-inflammatory cytokines overexpressed in many systemic inflammatory diseases. In Australia, they are registered for the treatment of several rheumatological, gastroenterological and dermatological indications. Despite increasing observational evidence for their use in off-label indications, there is a paucity of outcome research from the Australian hospital sector. Aims: To describe the off-label use of anti-TNFa and anakinra at a tertiary referral hospital in Queensland, Australia and consideration of a drug register to inform future clinical decision-making. Methods: We performed an in-depth retrospective chart audit of off-label treatment with anti-TNFa or anakinra at the Royal Brisbane and Women's Hospital from mid-2010 to mid-2014, linking demographic, phenotypic, pathology and outcome data with these drugs. Results: Off-label use was identified in 10 patients. The most frequent indications were sarcoidosis and dermatological conditions. Three patients required sequential therapy with a second anti-TNFa (total responses = 13). Complete response occurred in 46%, partial response in 38% and primary non-response in 8%. Response was unable to be determined in 8%. We recorded 14 adverse events (infections most common). Conclusion: This study suggests that anti-TNFa may be beneficial for some off-label indications (e.g. sarcoidosis). However, the observational design of this study (and pre-existing research) limits the ability to infer causality and generalise results. We propose the creation of a mandatory drug register to monitor off-label use. Whilst comparative efficacy cannot be established without a matched placebo arm, a register would enable some reporting on effectiveness in rare diseases and identify infrequent but serious adverse events.

DOI 10.1111/imj.13247
2016 McDougall DAJ, Martin J, Playford EG, Green B, 'Determination of a suitable voriconazole pharmacokinetic model for personalised dosing', Journal of Pharmacokinetics and Pharmacodynamics, 43 165-177 (2016) [C1]

© 2015, Springer Science+Business Media New York. Model based personalised dosing (MBPD) is a sophisticated form of individualised therapy, where a population pharmacokinetic (PK)... [more]

© 2015, Springer Science+Business Media New York. Model based personalised dosing (MBPD) is a sophisticated form of individualised therapy, where a population pharmacokinetic (PK) or pharmacodynamic model is utilised to estimate the dose required to reach a target exposure or effect. The choice of which model to implement in MBPD is a subjective decision. By choosing one model, information from the remaining models is ignored, as well as the rest of the literature base. This manuscript describes a methodology to develop a ¿hybrid¿ model for voriconazole that incorporated information from prior models in a biologically plausible manner. Voriconazole is a triazole antifungal with difficult to predict PK, although it does have a defined exposure¿response relationship. Nine population PK models of voriconazole were identified from the literature. The models differed significantly in structural components. The hybrid model contained a two-compartment disposition model with mixed linear and nonlinear time-dependent clearance. The parameters for the hybrid model were determined using simulation techniques. Validation of the hybrid model was assessed via visual predictive checks, which indicated the majority of the variability in the literature models was captured by the hybrid model. The predictive performance was assessed using four different sampling strategies of limited concentrations from ten richly PK sampled subjects to predict future concentrations. Overall, the hybrid model predicted future concentrations with good precision. Further prospective and retrospective validation of the hybrid model is required before it could be used in clinical practice.

DOI 10.1007/s10928-015-9462-9
Citations Scopus - 4Web of Science - 2
2016 Martin JH, Henry D, Gray J, Day R, Bochner F, Ferro A, et al., 'Achieving the World Health Organization's vision for clinical pharmacology.', Br J Clin Pharmacol, 81 223-227 (2016) [C1]
DOI 10.1111/bcp.12803
Citations Scopus - 3Web of Science - 2
2016 Martin JH, Bonomo Y, 'Medicinal cannabis in Australia: the missing links REPLY', MEDICAL JOURNAL OF AUSTRALIA, 205 (2016)
DOI 10.5694/mja16.00763
2016 Moore SP, Soerjomataram I, Green AC, Garvey G, Martin J, Valery PC, 'Breast cancer diagnosis, patterns of care and burden of disease in Queensland, Australia (1998¿2004): does being Indigenous make a difference?', International Journal of Public Health, 61 435-442 (2016) [C1]

© 2015, Swiss School of Public Health (SSPH+). Objectives: We compared patterns of care, comorbidity, disability-adjusted life-years (DALYs) and survival in Indigenous and non-Ind... [more]

© 2015, Swiss School of Public Health (SSPH+). Objectives: We compared patterns of care, comorbidity, disability-adjusted life-years (DALYs) and survival in Indigenous and non-Indigenous women with breast cancer in Queensland, Australia (1998¿2004). Methods: A cohort study of Indigenous (n¿=¿110) and non-Indigenous women (n¿=¿105), frequency matched on age and remoteness. We used Pearson¿s Chi-squared analysis to compare proportions, hazard models to assess survival differences and calculated disability-adjusted life years (DALYs). Results: Indigenous women were more likely to be socially disadvantaged (43 vs. 20¿%, p¿ < ¿0.01) have comorbidity (42 vs. 18¿% p¿ < ¿0.01), and have regional spread or distant metastasis (metastasis, 51 vs. 36¿%, p¿=¿0.02) than non-Indigenous women; there was no difference in treatment patterns. More Indigenous women died in the follow-up period (p¿=¿0.01). DALY¿s were 469 and 665 per 100,000 for Indigenous and non-Indigenous women, respectively, with a larger proportion of the burden attributed to premature death among the former (63 vs. 59¿%). Conclusions: Indigenous women with breast cancer received comparable treatment to their non-Indigenous counterparts. The higher proportion of DALYs related to early death in Indigenous women suggests higher fatality with breast cancer in this group. Later stage at diagnosis and higher comorbidity presence among Indigenous women reinforce the need for early detection and improved management of co-existing disease.

DOI 10.1007/s00038-015-0739-y
Citations Scopus - 2Web of Science - 2
2016 McDougall DAJ, Martin J, Playford EG, Green B, 'The Impact of Model-Misspecification on Model Based Personalised Dosing', AAPS Journal, 18 1244-1253 (2016) [C1]

© 2016, American Association of Pharmaceutical Scientists. Model Based Personalised Dosing (MBPD) requires a population pharmacokinetic (PK) or pharmacodynamic model to determine ... [more]

© 2016, American Association of Pharmaceutical Scientists. Model Based Personalised Dosing (MBPD) requires a population pharmacokinetic (PK) or pharmacodynamic model to determine the optimal dose of medication for an individual. Often several models are published, and the decision of which model is implemented in MBPD may have a large impact on its clinical utility. As quoted by Box, ¿all models are wrong, the practical question is how wrong can they be and still be useful¿. Voriconzole, a triazole antifungal and the example used in this manuscript, currently has nine population PK models published. To assess the impact of model-misspecification on MBPD, five structurally mis-specified models for voriconazole were developed. Intensive plasma concentrations were simulated for 100 virtual subjects. The dose adjustments required to reach a target exposure were determined by using the empirical Bayes estimates of the PK parameters under each of the mis-specified models. The predicted plasma concentrations and the probability of clinical outcomes, upon following the dose recommendations, were determined. Models that did not contain non-linear clearance performed poorly, with a median dose recommendation 155¿310¿mg higher than appropriate doses, when only one plasma concentration was available. Removal of body weight and CYP2C9 genotype as covariates had no clinically significant impact on outcomes. In summary, the removal of important structural components, such as non-linear clearance in the case of voriconazole, had a large impact on the clinical utility of MBPD. The removal of patient covariates, even highly influential covariates such as CYP2C9 genotype for voriconazole, had no clinical impact.

DOI 10.1208/s12248-016-9943-9
2016 Garvey G, Cunningham J, He VY, Janda M, Baade P, Sabesan S, et al., 'Health-related quality of life among Indigenous Australians diagnosed with cancer', QUALITY OF LIFE RESEARCH, 25 1999-2008 (2016) [C1]
DOI 10.1007/s11136-016-1233-6
Citations Scopus - 2Web of Science - 2
Co-authors Michael Fay
2016 Petrie S, Barras M, Lust K, Fagermo N, Allen J, Martin JH, 'Evaluation of therapeutic enoxaparin in a pregnant population at a tertiary hospital', Internal Medicine Journal, 46 826-833 (2016) [C1]

© 2016 Royal Australasian College of Physicians Background: Therapeutic anticoagulation with enoxaparin in pregnancy is complex due to varying pharmacokinetics and the increasing ... [more]

© 2016 Royal Australasian College of Physicians Background: Therapeutic anticoagulation with enoxaparin in pregnancy is complex due to varying pharmacokinetics and the increasing prevalence of obesity. There is limited evidence to support current dosing and monitoring strategies of enoxaparin in this population. Aim: To describe the current practice in therapeutic anticoagulation in the pregnant population at a tertiary institution. Methods: A retrospective study of pregnant women on therapeutic enoxaparin between January 2007 and December 2011. Results: Forty-four pregnant women requiring therapeutic anticoagulation were identified and divided into two groups, monitored with anti-factor Xa (AXA) concentrations and unmonitored. Fifty-five percent of monitored women were initiated on the recommended 1 mg/kg twice a day (bd) enoxaparin dose-strategy. Eighty-two percent of women were monitored; however, there was variability regarding the timing, frequency and subsequent dose adjustments from monitoring. Overall, as pregnancies progressed, there was both increasing dose adjustments and increasing frequency of monitoring. Fourteen women had a BMI over 30 kg/m 2 , and 13 of these women were monitored. Nine monitored obese women required doses less than 1 mg/kg/bd to maintain a therapeutic AXA level. Management appeared to be individualised. There were small numbers of toxicity events. Conclusion: Variation exists in dosing and monitoring practices for therapeutic enoxaparin in the pregnant population. Dosing obese patients using 1 mg/kg twice daily can lead to toxic AXA concentrations, and dose reductions are required to maintain a therapeutic range. A larger prospective study reviewing dose, AXA concentrations and outcome data is necessary to make dosing recommendations in this group.

DOI 10.1111/imj.13117
Citations Scopus - 1
2016 Martin J, Bonomo YA, 'Medicinal cannabis in Australia: the missing links', MEDICAL JOURNAL OF AUSTRALIA, 204 371-373 (2016) [C1]
DOI 10.5694/mja16.00234
Citations Scopus - 4Web of Science - 5
2016 Hayward KL, Valery PC, Cottrell WN, Irvine KM, Horsfall LU, Tallis CJ, et al., 'Prevalence of medication discrepancies in patients with cirrhosis: a pilot study.', BMC gastroenterology, 16 114 (2016) [C1]
DOI 10.1186/s12876-016-0530-4
Citations Scopus - 3Web of Science - 2
2016 Rundle-Thiele D, Head R, Cosgrove L, Martin JH, 'Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma', British Journal of Clinical Pharmacology, 81 199-209 (2016) [C1]

© 2015 The British Pharmacological Society. Glioblastoma is a brain neoplasm with limited 5-year survival rates. Developments of new treatment regimens that improve patient surviv... [more]

© 2015 The British Pharmacological Society. Glioblastoma is a brain neoplasm with limited 5-year survival rates. Developments of new treatment regimens that improve patient survival in patients with glioblastoma are needed. It is likely that a number of existing drugs used in other conditions have potential anticancer effects that offer significant survival benefit to glioblastoma patients. Identification of such drugs could provide a novel treatment paradigm.

DOI 10.1111/bcp.12785
Citations Scopus - 8Web of Science - 7
2016 Hayward KL, Powell EE, Irvine KM, Martin JH, 'Can paracetamol (acetaminophen) be administered to patients with liver impairment?', British Journal of Clinical Pharmacology, 81 210-222 (2016) [C1]

© 2015 The British Pharmacological Society. Although 60 years have passed since it became widely available on the therapeutic market, paracetamol dosage in patients with liver dis... [more]

© 2015 The British Pharmacological Society. Although 60 years have passed since it became widely available on the therapeutic market, paracetamol dosage in patients with liver disease remains a controversial subject. Fulminant hepatic failure has been a well documented consequence of paracetamol overdose since its introduction, while short and long term use have both been associated with elevation of liver transaminases, a surrogate marker for acute liver injury. From these reports it has been assumed that paracetamol use should be restricted or the dosage reduced in patients with chronic liver disease. We review the factors that have been purported to increase risk of hepatocellular injury from paracetamol and the pharmacokinetic alterations in different pathologies of chronic liver disease which may affect this risk. We postulate that inadvertent under-dosing may result in concentrations too low to enable efficacy. Specific research to improve the evidence base for prescribing paracetamol in patients with different aetiologies of chronic liver disease is needed.

DOI 10.1111/bcp.12802
Citations Scopus - 6Web of Science - 4
2016 Goulooze SC, Galettis P, Boddy AV, Martin JH, 'Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours', CANCER CHEMOTHERAPY AND PHARMACOLOGY, 78 209-216 (2016) [C1]
DOI 10.1007/s00280-016-3071-1
Citations Web of Science - 4
Co-authors Peter Galettis
2016 Dimmitt SB, Warren JB, Martin JH, Stampfer HG, 'Trading Lower HbA
DOI 10.1016/j.jacc.2016.06.045
2016 Ward MB, Reuter SE, Martin JH, 'How ¿Optimal¿ are Optimal Sampling Times for Tyrosine Kinase Inhibitors in Cancer? Practical Considerations', Clinical Pharmacokinetics, 55 1171-1177 (2016) [C1]

© 2016, Springer International Publishing Switzerland. Tyrosine kinase inhibitors have been marketed as a fixed dose, ¿one size fits all¿ treatment strategy. Physicians have also ... [more]

© 2016, Springer International Publishing Switzerland. Tyrosine kinase inhibitors have been marketed as a fixed dose, ¿one size fits all¿ treatment strategy. Physicians have also been interested in this method of dosing, knowing the complex planning of other current cancer therapies administered on a mg/m 2 or mg/kg basis and subsequent occurrence of dosing error or concern for underdosing. The ¿simple and safe¿ strategy of a single dose of tyrosine kinase inhibitor for cancer has thus been widely adopted. However, the benefits purported to exist in the clinical trials do not appear to be borne out in clinical practice, particularly in solid tumours. In order to investigate whether pharmacokinetic variability is a contributor to the variable outcomes, pharmacokinetic targets to enable individualisation of tyrosine kinase inhibitor administration are now emerging. Evidence suggests there is not a clear relationship of a single dose to maximum plasma concentration (C max ), steady-state trough concentration (C trough ) or area under the curve (AUC). Furthermore, a significant number of questions remain related to the specific timing and frequency of sample collection required to achieve optimal outcomes. This article reviews the wide variability in the literature on this topic, specifically the different pharmacokinetic targets of the same drug for different cancers, for different states of cancer, and changing pharmacokinetic parameters over a treatment interval in cancer. It appears the optimal sampling times to enable appropriate dose recommendations across patients and diseases may vary, and are not always trough concentrations at steady state. Importantly, the need to be pragmatic in a clinical setting is paramount. Lastly, international collaborations to increase sample size are highly recommended to ensure enough patients are sampled to be sure of a clinical benefit from this concentration-directed methodology.

DOI 10.1007/s40262-016-0394-3
Citations Scopus - 2Web of Science - 2
2016 Leung J, Martin J, McLaughlin D, 'Rural¿urban disparities in stage of breast cancer at diagnosis in Australian women', Australian Journal of Rural Health, 24 326-332 (2016) [C1]

© 2016 National Rural Health Alliance Inc. Objective: To examine urban¿rural differences and individual risk factors for a late stage of breast cancer at diagnosis in Australian w... [more]

© 2016 National Rural Health Alliance Inc. Objective: To examine urban¿rural differences and individual risk factors for a late stage of breast cancer at diagnosis in Australian women. Design: Individual-level longitudinal data were linked with cancer registry data from New South Wales (New South Wales Cancer Registry linked by the Centre for Health Record Linkage (CHeReL)), Queensland (Queensland Cancer Registry) and Victoria (The Cancer Council Victoria). Setting: Participants were drawn from the Australian Longitudinal Study on Women¿s Health 1946-1951 cohort (n = 13 715). Participants: The sample included 195 women identified from the linked cancer registry data with a breast cancer diagnosis. Interventions: Rural or urban residence was measured using Accessibility/Remoteness Index of Australia Plus (ARIA+). Individual characteristics and socio-demographic variables examined included survey year, menopausal status, country of birth, education and marital status. Main outcome measures: A late stage of breast cancer at diagnosis was defined based on the TNM Classification of Malignant Tumours. Results: A late stage of breast cancer diagnosis was observed in 36% of women residing in urban areas and 40% of women residing in rural areas. After adjusting for individual characteristics, we found that obesity was the strongest risk factor for a late stage of breast cancer at diagnosis. Conclusions: Given that women are becoming increasingly obese, and that the rate of obesity is higher in the Australian rural population, this paper provides further evidence for targeting interventions for obesity, particularly in rural Australia, as a public health priority.

DOI 10.1111/ajr.12271
Citations Scopus - 3Web of Science - 3
2016 Reuter SE, Martin JH, 'Pharmacokinetics of Cannabis in Cancer Cachexia-Anorexia Syndrome', Clinical Pharmacokinetics, 55 807-812 (2016) [C1]

© 2016, Springer International Publishing Switzerland. Anorexia can affect up to 90¿% of people with advanced cancer. It is a complex symptom associated with changes in taste, lac... [more]

© 2016, Springer International Publishing Switzerland. Anorexia can affect up to 90¿% of people with advanced cancer. It is a complex symptom associated with changes in taste, lack of hunger at mealtimes and lack of food enjoyment. Associated weight loss is part of the physical decline that occurs as cancer worsens. Weight loss can also occur from cachexia, the increased metabolism of energy due to raised inflammatory cytokines, liver metastases and other factors seen in several advanced cancers. Independent of anorexia, although frequently associated (where it is referred to as the cachexia-anorexia syndrome), it accounts for a significant amount of morbidity and deaths in people with cancer. In particular, quality of life for the patient and the family is significantly affected with this syndrome as it causes anxiety and distress. Therefore, it is important that research into therapies is undertaken, particularly focusing on an understanding of the pharmacokinetic properties of compounds in this cachexic population. Cannabinoids are one such group of therapies that have received a large amount of media focus recently. However, there appears to be a lack on rigorous pharmacokinetic data of these complex and varied compounds in the cachexic population. Similarly, there is a lack of pharmacokinetic data in any population group for the non- tetrahydrocannabinol (THC) and cannabidiol (CBD) cannabinoids (often due to the lack of analytical standards for quantification). This review will thus examine the pharmacokinetics of major cannabinoids i.e. THC and CBD in a cancer population. Overall, based on the current literature, evidence for the use of cannabinoids for the treatment of cancer-related cachexia-anorexia syndrome remains equivocal. A high-quality, rigorous, phase I/II study to elicit pharmacokinetic dose¿concentration and concentration¿response data, with a clinically acceptable mode of delivery to reduce intrapatient variability and enable more consistent bioavailability is needed in this population.

DOI 10.1007/s40262-015-0363-2
Citations Scopus - 4Web of Science - 3
2016 Martin J, Shenfield G, 'The hazards of rapid approval of new drugs', AUSTRALIAN PRESCRIBER, 39 2-3 (2016)
DOI 10.18773/austprescr.2016.005
Citations Web of Science - 3
2016 Denaro C, Martin J, 'The challenge of costly drugsone', AUSTRALIAN PRESCRIBER, 39 72-74 (2016)
DOI 10.18773/austprescr.2016.037
Citations Scopus - 1Web of Science - 1
2016 Fay MF, Head R, Sminia P, Dowson N, Cosgrove L, Rose SE, Martin JH, 'Valproate in Adjuvant Glioblastoma Treatment', JOURNAL OF CLINICAL ONCOLOGY, 34 3105-+ (2016)
DOI 10.1200/JCO.2016.67.2162
Citations Scopus - 6Web of Science - 5
Co-authors Michael Fay
2015 Hubbard RE, Peel NM, Scott IA, Martin JH, Smith A, Pillans PI, et al., 'Polypharmacy among inpatients aged 70 years or older in Australia', MEDICAL JOURNAL OF AUSTRALIA, 202 373-+ (2015)
DOI 10.5694/mja13.00172
Citations Web of Science - 25
2015 O'Hara K, Wright IMR, Schneider JJ, Jones AL, Martin JH, 'Pharmacokinetics in neonatal prescribing: Evidence base, paradigms and the future', British Journal of Clinical Pharmacology, 80 1281-1288 (2015) [C1]

© 2015 The British Pharmacological Society. Paediatric patients, particularly preterm neonates, present many pharmacological challenges. Due to the difficulty in conducting clinic... [more]

© 2015 The British Pharmacological Society. Paediatric patients, particularly preterm neonates, present many pharmacological challenges. Due to the difficulty in conducting clinical trials in these populations dosing information is often extrapolated from adult populations. As the processes of absorption, distribution, metabolism and excretion of drugs change throughout growth and development extrapolation presents risk of over or underestimating the doses required. Information about the development these processes, particularly drug metabolism pathways, is still limited with weight based dose adjustment presenting the best method of estimating pharmacokinetic changes due to growth and development. New innovations in pharmacokinetic research, such as population pharmacokinetic modelling, present unique opportunities to conduct clinical trials in these populations improving the safety and effectiveness of the drugs used. More research is required into this area to ensure the best outcomes for our most vulnerable patients.

DOI 10.1111/bcp.12741
Citations Scopus - 5Web of Science - 7
Co-authors Jennifer Schneider, Ian Wright
2015 Martin JH, Ferro A, 'From an evolutionary perspective, all 'new' antimicrobial targets are old: Time to think outside the box', British Journal of Clinical Pharmacology, 79 165-167 (2015) [C3]
DOI 10.1111/bcp.12385
Citations Scopus - 2Web of Science - 2
2015 Lim AE, Tate JR, Clarke D, Norris RL, Morris RG, Martin JH, 'Clinical Consequences of a Miscalibrated Digoxin Immunoassay', THERAPEUTIC DRUG MONITORING, 37 104-109 (2015) [C1]
DOI 10.1097/FTD.0000000000000118
Citations Scopus - 1Web of Science - 1
2015 Diaz A, Moore SP, Martin JH, Green AC, Garvey G, Valery PC, 'Factors associated with cancer-specific and overall survival among indigenous and non-indigenous gynecologic cancer patients in Queensland, Australia: A matched cohort study', International Journal of Gynecological Cancer, 25 542-547 (2015) [C1]

Copyright © 2015 by IGCS and ESGO. Objective: Aboriginal and Torres Strait Islander women have a higher mortality rate due to gynecologic cancer compared with non-Indigenous women... [more]

Copyright © 2015 by IGCS and ESGO. Objective: Aboriginal and Torres Strait Islander women have a higher mortality rate due to gynecologic cancer compared with non-Indigenous women. For cervical cancer, Australian Indigenous women are less likely to survive 5 years following diagnoses than non-Indigenous women. This study investigates the factors associated with gynecologic cancer treatment and survival among Queensland indigenous and non-Indigenous women. Methods: Australian Indigenous women diagnosed with uterine, cervical, ovarian, or other gynecologic cancers during 1998-2004 in the public hospital system were included. They were frequency matched on age (±5 years), residential remoteness, and cancer type to a random sample of non-Indigenous women. One- and 5-year cancer-specific survival was examined according to Indigenous status using Cox proportional hazards regression. Results: Indigenous women (n = 137) compared with non-Indigenous women (n = 120) were less likely to be diagnosed with localized disease (49% vs 65%, P = 0.02) and had more comorbidities (52% vs 21%, P < 0.001). Indigenous women were less likely to receive any cancer treatment compared with non-Indigenous women (91% vs 98%, P = 0.01), although when excluding those with metastatic cancer, there was no significant difference in uptake of treatment (95% vs 91%, respectively, P = 0.31). Among those who did undergo treatment, there was no difference in time to treatment (median difference 0.5 days, P = 0.98). Gynecologic cancer-specific survival differences between Indigenous and non-Indigenous women were most prominent in the first year following diagnosis (hazard ratio [HR], 1.89; 95% confidence interval [CI] , 1.06-3.38) and were no longer significant 5 years after diagnosis (HR, 1.47 [95% CI, 0.97-2.25]). For cervical cancer, crude 1-year survival was poorer for Indigenous women compared with non-Indigenous women (HR, 2.46 [95% CI, 1.03-5.90] ), but was no different when adjusted for stage and treatment of cancer (HR, 1.00 [95% CI, 0.45-2.24]). Conclusions: Improving the early diagnosis of cervical cancer in Indigenous women may increase cancer-specific survival in the year following diagnosis.

DOI 10.1097/IGC.0000000000000375
Citations Scopus - 4Web of Science - 5
2015 Lindsay J, Dooley M, Martin J, Fay M, Kearney A, Khatun M, Barras M, 'The development and evaluation of an oncological palliative care deprescribing guideline: the 'OncPal deprescribing guideline'', SUPPORTIVE CARE IN CANCER, 23 71-78 (2015) [C1]
DOI 10.1007/s00520-014-2322-0
Citations Scopus - 16Web of Science - 14
Co-authors Michael Fay
2015 Liu X, Vitetta L, Kostner K, Crompton D, Williams G, Brown WJ, et al., 'The effects of tai chi in centrally obese adults with depression symptoms', Evidence-based Complementary and Alternative Medicine, 2015 (2015) [C1]

© 2015 Xin Liu et al. This study examined the effects of Tai Chi, a low-impact mind-body movement therapy, on severity of depression, anxiety, and stress symptoms in centrally obe... [more]

© 2015 Xin Liu et al. This study examined the effects of Tai Chi, a low-impact mind-body movement therapy, on severity of depression, anxiety, and stress symptoms in centrally obese people with elevated depression symptoms. In total, 213 participants were randomized to a 24-week Tai Chi intervention program or a wait-list control group. Assessments were conducted at baseline and 12 and 24 weeks. Outcomes were severity of depression, anxiety, and stress symptoms, leg strength, central obesity, and other measures of metabolic symptom. There were statistically significant between-group differences in favor of the Tai Chi group in depression (mean difference = -5.6 units, P < 0.001), anxiety (-2.3 units, P < 0.01), and stress (-3.6 units, P < 0.001) symptom scores and leg strength (1.1 units, P < 0.001) at 12 weeks. These changes were further improved or maintained in the Tai Chi group relative to the control group during the second 12 weeks of follow-up. Tai Chi appears to be beneficial for reducing severity of depression, anxiety, and stress and leg strength in centrally obese people with depression symptoms. More studies with longer follow-up are needed to confirm the findings. This trial is registered with ACTRN12613000010796.

DOI 10.1155/2015/879712
Citations Scopus - 9
2015 Allemani C, Weir HK, Carreira H, Harewood R, Spika D, Wang XS, et al., 'Global surveillance of cancer survival 1995-2009: Analysis of individual data for 25 676 887 patients from 279 population-based registries in 67 countries (CONCORD-2)', The Lancet, 385 977-1010 (2015)

© 2015 Allemani et al. Open Access article distributed under the terms of CC BY. Background Worldwide data for cancer survival are scarce. We aimed to initiate worldwide surveilla... [more]

© 2015 Allemani et al. Open Access article distributed under the terms of CC BY. Background Worldwide data for cancer survival are scarce. We aimed to initiate worldwide surveillance of cancer survival by central analysis of population-based registry data, as a metric of the effectiveness of health systems, and to inform global policy on cancer control. Methods Individual tumour records were submitted by 279 population-based cancer registries in 67 countries for 25·7 million adults (age 15-99 years) and 75 000 children (age 0-14 years) diagnosed with cancer during 1995-2009 and followed up to Dec 31, 2009, or later. We looked at cancers of the stomach, colon, rectum, liver, lung, breast (women), cervix, ovary, and prostate in adults, and adult and childhood leukaemia. Standardised quality control procedures were applied; errors were corrected by the registry concerned. We estimated 5-year net survival, adjusted for background mortality in every country or region by age (single year), sex, and calendar year, and by race or ethnic origin in some countries. Estimates were age-standardised with the International Cancer Survival Standard weights. Findings 5-year survival from colon, rectal, and breast cancers has increased steadily in most developed countries. For patients diagnosed during 2005-09, survival for colon and rectal cancer reached 60% or more in 22 countries around the world; for breast cancer, 5-year survival rose to 85% or higher in 17 countries worldwide. Liver and lung cancer remain lethal in all nations: for both cancers, 5-year survival is below 20% everywhere in Europe, in the range 15-19% in North America, and as low as 7-9% in Mongolia and Thailand. Striking rises in 5-year survival from prostate cancer have occurred in many countries: survival rose by 10-20% between 1995-99 and 2005-09 in 22 countries in South America, Asia, and Europe, but survival still varies widely around the world, from less than 60% in Bulgaria and Thailand to 95% or more in Brazil, Puerto Rico, and the USA. For cervical cancer, national estimates of 5-year survival range from less than 50% to more than 70%; regional variations are much wider, and improvements between 1995-99 and 2005-09 have generally been slight. For women diagnosed with ovarian cancer in 2005-09, 5-year survival was 40% or higher only in Ecuador, the USA, and 17 countries in Asia and Europe. 5-year survival for stomach cancer in 2005-09 was high (54-58%) in Japan and South Korea, compared with less than 40% in other countries. By contrast, 5-year survival from adult leukaemia in Japan and South Korea (18-23%) is lower than in most other countries. 5-year survival from childhood acute lymphoblastic leukaemia is less than 60% in several countries, but as high as 90% in Canada and four European countries, which suggests major deficiencies in the management of a largely curable disease. Interpretation International comparison of survival trends reveals very wide differences that are likely to be attributable to differences in access to early diagnosis and optimum treatment. Continuous worldwide surveillance of cancer survival should become an indispensable source of information for cancer patients and researchers and a stimulus for politicians to improve health policy and health-care systems. Funding Canadian Partnership Against Cancer (Toronto, Canada), Cancer Focus Northern Ireland (Belfast, UK), Cancer Institute New South Wales (Sydney, Australia), Cancer Research UK (London, UK), Centers for Disease Control and Prevention (Atlanta, GA, USA), Swiss Re (London, UK), Swiss Cancer Research foundation (Bern, Switzerland), Swiss Cancer League (Bern, Switzerland), and University of Kentucky (Lexington, KY, USA).

DOI 10.1016/S0140-6736(14)62038-9
Citations Scopus - 571
2015 Fay M, Head R, Martin J, 'Where is the radiobiology and pharmacology research to improve outcomes in glioblastoma?', Journal of Neuro-Oncology, (2015) [C1]

Personalized medicine has been helpful for drug development in diseases with single and relatively stable gene mutations. The benefit for complex solid tumours with heterogeneous ... [more]

Personalized medicine has been helpful for drug development in diseases with single and relatively stable gene mutations. The benefit for complex solid tumours with heterogeneous and changing genetic profiles is less clear. Whether it is efficient to continue diverting resources from combined biological and pharmacological approaches to trial new and existing genetic ¿targeted therapies¿ for brain tumours is unknown but of developing concern in resource constrained environments.

DOI 10.1007/s11060-015-1816-z
Citations Scopus - 1Web of Science - 1
Co-authors Michael Fay
2015 Valery PC, Powell E, Moses N, Volk ML, McPhail SM, Clark PJ, Martin J, 'Systematic review: unmet supportive care needs in people diagnosed with chronic liver disease', BMJ OPEN, 5 (2015) [C1]
DOI 10.1136/bmjopen-2014-007451
Citations Scopus - 9Web of Science - 7
2015 Rundle-Thiele D, Day B, Stringer B, Fay M, Martin J, Jeffree RL, et al., 'Using the apparent diffusion coefficient to identifying MGMT promoter methylation status early in glioblastoma: Importance of analytical method', Journal of Medical Radiation Sciences, 62 92-98 (2015) [C1]

© 2015. Introduction: Accurate knowledge of O &lt; sup &gt; 6 &lt; /sup &gt; -methylguanine methyltransferase (MGMT) gene promoter subtype in patients with glioblastoma (GBM) is i... [more]

© 2015. Introduction: Accurate knowledge of O < sup > 6 < /sup > -methylguanine methyltransferase (MGMT) gene promoter subtype in patients with glioblastoma (GBM) is important for treatment. However, this test is not always available. Pre-operative diffusion MRI (dMRI) can be used to probe tumour biology using the apparent diffusion coefficient (ADC); however, its ability to act as a surrogate to predict MGMT status has shown mixed results. We investigated whether this was due to variations in the method used to analyse ADC. Methods: We undertook a retrospective study of 32 patients with GBM who had MGMT status measured. Matching pre-operative MRI data were used to calculate the ADC within contrast enhancing regions of tumour. The relationship between ADC and MGMT was examined using two published ADC methods. Results: A strong trend between a measure of 'minimum ADC' and methylation status was seen. An elevated minimum ADC was more likely in the methylated compared to the unmethylated MGMT group (U = 56, P = 0.0561). In contrast, utilising a two-mixture model histogram approach, a significant reduction in mean measure of the 'low ADC' component within the histogram was associated with an MGMT promoter methylation subtype (P < 0.0246). Conclusion: This study shows that within the same patient cohort, the method selected to analyse ADC measures has a significant bearing on the use of that metric as a surrogate marker of MGMT status. Thus for dMRI data to be clinically useful, consistent methods of data analysis need to be established prior to establishing any relationship with genetic or epigenetic profiling.

DOI 10.1002/jmrs.103
Citations Scopus - 8Web of Science - 8
Co-authors Michael Fay
2015 Scott IA, Hilmer SN, Reeve E, Potter K, Couteur DL, Rigby D, et al., 'Reducing inappropriate polypharmacy: The process of deprescribing', JAMA Internal Medicine, 175 827-834 (2015) [C1]

© Copyright 2015 American Medical Association. All rights reserved. Inappropriate polypharmacy, especially in older people, imposes a substantial burden of adverse drug events, il... [more]

© Copyright 2015 American Medical Association. All rights reserved. Inappropriate polypharmacy, especially in older people, imposes a substantial burden of adverse drug events, ill health, disability, hospitalization, and even death. The single most important predictor of inappropriate prescribing and risk of adverse drug events in older patients is the number of prescribed drugs. Deprescribing is the process of tapering or stopping drugs, aimed at minimizing polypharmacy and improving patient outcomes. Evidence of efficacy for deprescribing is emerging from randomized trials and observational studies. A deprescribing protocol is proposed comprising 5 steps: (1) ascertain all drugs the patient is currently takin g and the reasons for each one; (2) consider overall risk of drug-induced harm in individual patients in determining the required intensity of deprescribing intervention; (3) assess each drug in regard to its current or future benefit potential compared with current or future harm or burden potential; (4) prioritize drugs for discontinuation that have the lowest benefit-harm ratio and lowest likelihood of adverse withdrawal reactions or disease rebound syndromes; and (5) implement a discontinuation regimen and monitor patients closely for improvement in outcomes or onset of adverse effects. Whereas patient and prescriber barriers to deprescribing exist, resources and strategies are available that facilitate deliberate yet judicious deprescribing and deserve wider application.

DOI 10.1001/jamainternmed.2015.0324
Citations Scopus - 239Web of Science - 200
2015 Hosein AN, Lim YC, Day B, Stringer B, Rose S, Head R, et al., 'The effect of valproic acid in combination with irradiation and temozolomide on primary human glioblastoma cells', Journal of Neuro-Oncology, 122 263-271 (2015) [C1]

© 2015, Springer Science+Business Media New York. Glioblastoma multiforme (GBM) has nearly uniformly fatal with a median survival of less than 2¿years. While there have not been a... [more]

© 2015, Springer Science+Business Media New York. Glioblastoma multiforme (GBM) has nearly uniformly fatal with a median survival of less than 2¿years. While there have not been any novel anti-GBM therapeutics approved for many years, there has been the gradual accumulation of clinical data suggesting that the widely used anti-convulsant agent, valproic acid (VPA) may significantly prolong survival in GBM patients. This pre-clinical study aimed to determine the potential clinical utility of VPA in the treatment of GBM. Primary GBM cells were treated with VPA as a monotherapy and in combination with temozolomide and irradiation. At clinically achievable concentrations, VPA was shown to be effective as a monotherapy agent in the five primary lines tested. VPA was then used as a sensitizing agent to in vitro radiation and showed significant augmentation of in vitro irradiation therapy. In addition, when VPA, radiation and temozolomide were combined an additive, rather than synergistic effect was noted. Gene expression profiling demonstrated close clustering of triple treated cells with VPA mono-treated cells while untreated cells clustered closer with TMZ-irradiation dual treated cells. These microarray data suggest a dominant role of VPA at the gene expression level when combining these different treatment options. Moreover, in an in vivo tumor transplantation model, we were able to demonstrate an increase in animal survival when cells were pre-treated with irradiation-VPA and when triple treated. These findings provide a significant rationale for the investigation of VPA in the treatment of GBM patients.

DOI 10.1007/s11060-014-1713-x
Citations Scopus - 15Web of Science - 14
Co-authors Michael Fay
2015 Hubbard RE, Peel NM, Scott IA, Martin JH, Smith A, Pillans PI, et al., 'Polypharmacy among inpatients aged 70 years or older in Australia', MEDICAL JOURNAL OF AUSTRALIA, 202 373-+ (2015) [C1]
DOI 10.5694/mja13.00172
Citations Scopus - 31Web of Science - 27
2015 Martin JH, Phillips E, Thomas D, Somogyi AA, 'Adding the 'medicines' back into personalized medicine to improve cancer treatment outcomes', British Journal of Clinical Pharmacology, 80 929-931 (2015) [C3]
DOI 10.1111/bcp.12690
Citations Scopus - 3Web of Science - 2
2014 Williams MM, Taylor PJ, Page CB, Martin JH, 'Clinical research in synthetic cannabinoids - do we need a national approach?', Med J Aust, 201 317-319 (2014) [C3]
Citations Scopus - 3Web of Science - 1
2014 Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O'Moore-Sullivan TM, Lee P, et al., 'Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease', Clinical Gastroenterology and Hepatology, 12 2092-2103 (2014) [C1]

© 2014 AGA Institute. Background &amp; Aims: Nonalcoholic fatty liver disease (NAFLD), characterized by accumulation of hepatic triglycerides (steatosis), is associated with abd... [more]

© 2014 AGA Institute. Background & Aims: Nonalcoholic fatty liver disease (NAFLD), characterized by accumulation of hepatic triglycerides (steatosis), is associated with abdominal obesity, insulin resistance, and inflammation. Although weight loss via calorie restriction reduces features of NAFLD, there is no pharmacologic therapy. Resveratrol is a polyphenol that prevents high-energy diet-induced steatosis and insulin resistance in animals by up-regulating pathways that regulate energy metabolism. We performed a placebo-controlled trial to assess the effects of resveratrol in patients with NAFLD. Methods: Overweight or obese men diagnosed with NAFLD were recruited from hepatology outpatient clinics in Brisbane, Australia from 2011 through 2012. They were randomly assigned to groups given 3000 mg resveratrol (n= 10) or placebo (n= 10) daily for 8 weeks. Outcomes included insulin resistance (assessed by the euglycemic-hyperinsulinemic clamp), hepatic steatosis, and abdominal fat distribution (assessed by magnetic resonance spectroscopy and imaging). Plasma markers of inflammation, as well as metabolic, hepatic, and antioxidant function, were measured; transcription of target genes was measured in peripheral blood mononuclear cells. Resveratrol pharmacokinetics and safety were assessed. Results: Eight-week administration of resveratrol did not reduce insulin resistance, steatosis, or abdominal fat distribution when compared with baseline. No change was observed in plasma lipids or antioxidant activity. Levels of alanine and aspartate aminotransferases increased significantly among patients in the resveratrol group until week 6 when compared with the placebo group. Resveratrol did not significantly alter transcription of NQO1, PTP1B, IL6, or HO1 in peripheral blood mononuclear cells. Resveratrol was well-tolerated. Conclusions: Eight weeks administration of resveratrol did not significantly improve any features of NAFLD, compared with placebo, but it increased hepatic stress, based on observed increases in levels of liver enzymes. Further studies are needed to determine whether agents that are purported to mimic calorie restriction, such as resveratrol, are safe and effective for complications of obesity. Clinical trials registration no: ACTRN12612001135808.

DOI 10.1016/j.cgh.2014.02.024
Citations Scopus - 90Web of Science - 70
2014 Hollingworth SA, Ostini R, Michael D, Martin J, Susan T, 'Use of Ezetimibe in Australia', PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 23 130-131 (2014)
2014 Morais C, Small D, Vesey D, Martin JH, Johnson D, Gobe G, 'Fibronectin and transforming growth factor beta contribute to erythropoietin resistance and maladaptive cardiac hypertrophy', Biochemical and Biophysical Research Communications, 444 332-337 (2014)
DOI 10.1016/j.bbrc.2014.01.047
Citations Scopus - 4Web of Science - 4
2014 Theile DE, Scott IA, Martin JH, Gavrilidis A, 'Enabling the success of academic health science centres in Australia: where is the leadership?', The Medical journal of Australia, 201 636-638 (2014) [C3]
DOI 10.5694/mja14.00992
Citations Scopus - 1Web of Science - 1
2014 Lindsay J, Dooley M, Martin J, Fay M, Kearney A, Barras M, 'Reducing potentially inappropriate medications in palliative cancer patients: evidence to support deprescribing approaches', SUPPORTIVE CARE IN CANCER, 22 1113-1119 (2014)
DOI 10.1007/s00520-013-2098-7
Citations Scopus - 17Web of Science - 14
Co-authors Michael Fay
2014 Leung J, McKenzie S, Martin J, McLaughlin D, 'Effect of rurality on screening for breast cancer: a systematic review and meta-analysis comparing mammography', Rural and remote health, 14 2730 (2014)

INTRODUCTION: The lower breast cancer survival rate observed among rural women may be related to differences in screening access and utilization. We evaluated existing evidence fo... [more]

INTRODUCTION: The lower breast cancer survival rate observed among rural women may be related to differences in screening access and utilization. We evaluated existing evidence for rural and urban differences in mammography service use in adult women. METHODS: A systematic search was conducted on 4 April 2012 and updated on 1 November 2012, which yielded 28 studies for inclusion. RESULTS: The rural population was less likely to have mammographic breast screening, and this difference was consistent in various areas of the USA as well as across a number of other countries. Meta-analyses using random effects models showed that women residing in rural areas were less likely than urban women to have ever had a mammogram (odds ratio (OR)=0.74, 95% confidence interval (CI)=0.62-0.89) or to have an up-to-date mammogram (OR=0.59, 95%CI=0.49-0.70). CONCLUSIONS: Mammography is currently the best tool for the early detection and diagnosis of breast cancer. The rural disadvantage this review has identified may contribute to the lower breast cancer survival among women living outside urban areas.

Citations Scopus - 17Web of Science - 13
2014 Sullivan CM, Staib A, Flores J, Aggarwal L, Scanlon A, Martin JH, Scott IA, 'Aiming to be NEAT: Safely improving and sustaining access to emergency care in a tertiary referral hospital', Australian Health Review, 38 564-574 (2014)
DOI 10.1071/AH14083
Citations Scopus - 23Web of Science - 22
2014 Fagan KJ, Irvine KM, McWhinney BC, Fletcher LM, Horsfall LU, Johnson L, et al., 'Diagnostic sensitivity of carbohydrate deficient transferrin in heavy drinkers', BMC GASTROENTEROLOGY, 14 (2014)
DOI 10.1186/1471-230X-14-97
Citations Scopus - 11Web of Science - 11
2014 Moore SP, Green AC, Bray F, Garvey G, Coory M, Martin J, Valery PC, 'Survival disparities in Australia: an analysis of patterns of care and comorbidities among indigenous and non-indigenous cancer patients', BMC CANCER, 14 (2014)
DOI 10.1186/1471-2407-14-517
Citations Scopus - 19Web of Science - 18
2014 Carroll JP, Protani MM, Nguyen L, Cheng ME, Fay M, Saleem M, et al., 'Toxicity and tolerability of adjuvant breast cancer chemotherapy in obese women.', Med Oncol, 31 881-881 (2014)
DOI 10.1007/s12032-014-0881-z
Citations Scopus - 9Web of Science - 8
Co-authors Michael Fay
2014 Leung J, McKenzie S, Martin JH, Dobson A, McLaughlin D, 'Longitudinal patterns of breast cancer screening: Mammography, clinical, and breast self-examinations in a rural and urban setting', Women's Health Issues, 24 e139-e146 (2014)
DOI 10.1016/j.whi.2013.11.005
Citations Scopus - 4Web of Science - 3
2014 Fay MF, Martin JH, Rose S, 'New imaging techniques for more effective treatment in glioblastoma', Internal Medicine Journal, 44 5-6 (2014) [C3]
DOI 10.1111/imj.12331
Citations Scopus - 2Web of Science - 2
Co-authors Michael Fay
2014 Martin JH, Coombes I, 'Mortality from common drug interactions systems, knowledge and clinical reasoning to optimise prescribing', Internal Medicine Journal, 44 621-624 (2014) [C3]
DOI 10.1111/imj.12473
Citations Scopus - 2Web of Science - 2
2014 Chachay VS, Macdonald GA, Martin JH, Whitehead JP, O'Moore-Sullivan TM, Lee P, et al., 'Resveratrol Does Not Benefit Patients With Nonalcoholic Fatty Liver Disease', Clinical Gastroenterology and Hepatology, 12 2092-2103 (2014) [C1]

© 2014 AGA Institute. Background &amp; Aims: Nonalcoholic fatty liver disease (NAFLD), characterized by accumulation of hepatic triglycerides (steatosis), is associated with abd... [more]

© 2014 AGA Institute. Background & Aims: Nonalcoholic fatty liver disease (NAFLD), characterized by accumulation of hepatic triglycerides (steatosis), is associated with abdominal obesity, insulin resistance, and inflammation. Although weight loss via calorie restriction reduces features of NAFLD, there is no pharmacologic therapy. Resveratrol is a polyphenol that prevents high-energy diet-induced steatosis and insulin resistance in animals by up-regulating pathways that regulate energy metabolism. We performed a placebo-controlled trial to assess the effects of resveratrol in patients with NAFLD. Methods: Overweight or obese men diagnosed with NAFLD were recruited from hepatology outpatient clinics in Brisbane, Australia from 2011 through 2012. They were randomly assigned to groups given 3000 mg resveratrol (n= 10) or placebo (n= 10) daily for 8 weeks. Outcomes included insulin resistance (assessed by the euglycemic-hyperinsulinemic clamp), hepatic steatosis, and abdominal fat distribution (assessed by magnetic resonance spectroscopy and imaging). Plasma markers of inflammation, as well as metabolic, hepatic, and antioxidant function, were measured; transcription of target genes was measured in peripheral blood mononuclear cells. Resveratrol pharmacokinetics and safety were assessed. Results: Eight-week administration of resveratrol did not reduce insulin resistance, steatosis, or abdominal fat distribution when compared with baseline. No change was observed in plasma lipids or antioxidant activity. Levels of alanine and aspartate aminotransferases increased significantly among patients in the resveratrol group until week 6 when compared with the placebo group. Resveratrol did not significantly alter transcription of NQO1, PTP1B, IL6, or HO1 in peripheral blood mononuclear cells. Resveratrol was well-tolerated. Conclusions: Eight weeks administration of resveratrol did not significantly improve any features of NAFLD, compared with placebo, but it increased hepatic stress, based on observed increases in levels of liver enzymes. Further studies are needed to determine whether agents that are purported to mimic calorie restriction, such as resveratrol, are safe and effective for complications of obesity. Clinical trials registration no: ACTRN12612001135808.

DOI 10.1016/j.cgh.2014.02.024
Citations Scopus - 83
2014 Arpon DR, Gandhi MK, Martin JH, 'A new frontier in haematology - combining pharmacokinetic with pharmacodynamic factors to improve choice and dose of drug', BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 78 274-281 (2014)
DOI 10.1111/bcp.12318
Citations Scopus - 3Web of Science - 3
2014 Jellis CL, Sacre JW, Wright J, Jenkins C, Haluska B, Jeffriess L, et al., 'Biomarker and imaging responses to spironolactone in subclinical diabetic cardiomyopathy', EUROPEAN HEART JOURNAL-CARDIOVASCULAR IMAGING, 15 776-786 (2014) [C1]
DOI 10.1093/ehjci/jeu013
Citations Scopus - 7Web of Science - 7
2013 Martin JH, Fagan K, Irvine K, McWhinney B, Fletcher L, Horsfall L, et al., 'BMI but not aetiology or stage of liver disease affects the diagnostic sensitivity of carbohydrate deficient transferrin', Alcoholism: Clinical and Experimental Research, 37 1771-1778 (2013) [C1]
DOI 10.1111/acer.12143
2013 Martin JH, Chachay V, Prins J, Whitehead J, O'Moore-Sullivan T, Lee P, et al., 'Investigating the clinical effect of resveratrol in non-alcoholic fatty liver disease: a randomised, double blind, placebo-controlled trial', Journal of Gastroenterology and Hepatology, 28 78-79 (2013)
2013 Forbes MP, Raj AS, Martin J, Lampe G, Powell EE, 'Khat-associated hepatitis', Medical Journal of Australia, 199 498-499 (2013)
DOI 10.5694/mja13.10951
Citations Scopus - 3Web of Science - 4
2013 Putt MT, Udy AA, Jarrett P, Martin J, Hennig S, Salmon N, et al., 'Phenytoin loading doses in adult critical care patients: Does current practice achieve adequate drug levels?', Anaesthesia and Intensive Care, 41 602-609 (2013)

Phenytoin is regularly employed in the critically ill for prophylaxis against or treatment of seizure disorders. No prior studies have examined current dosing practices in an Aust... [more]

Phenytoin is regularly employed in the critically ill for prophylaxis against or treatment of seizure disorders. No prior studies have examined current dosing practices in an Australasian intensive care unit (ICU) sett ing. The aims of this study were to: a) describe the adequacy of contemporary dosing in respect to free and total serum phenytoin concentrations; b) identify factors associated with therapeutic drug concentrations; and c) examine the accuracy of predictive equations that estimate free concentrations in this setting. All patients receiving a loading dose of phenytoin in a tertiary-level ICU were eligible for enrolment; 53 patients were enrolled in the study. Serum samples to determine free and total phenytoin concentrations (measured by high performance liquid chromatography) were then drawn prior to the following dose. Free concentrations below the recommended target ( < 1 mg/l) were considered as suboptimal. The most common indication for phenytoin loading was traumatic brain injury (49%) and the mean administered dose was 14.5 (3.66) mg/kg. Twenty-six patients (49%) had suboptimal trough free concentrations, although this subgroup was significantly heavier and therefore received a lower per kilogram dose (12.8 [3.1] vs 16.3 [3.4] mg/kg, P=0.001). In multivariate analysis, larger weight adjusted doses (P=0.018), higher albumin concentration (P=0.034) and receiving phenytoin for an indication other than seizure (P=0.035), were associated with a greater likelihood of adequate concentrations. In conclusion, phenytoin dosing remains complex in critically ill patients, although lower per kilogram loading doses are strongly associated with free concentrations below the desired target.

Citations Scopus - 1Web of Science - 1
2013 Lucas C, Martin J, 'Smoking and drug interactions', Australian Prescriber, 36 102-104 (2013)

When patients enter hospital they may have to stop smoking abruptly if the hospital has a &apos;no smoking&apos; policy. Abrupt smoking cessation can affect the metabolism of drug... [more]

When patients enter hospital they may have to stop smoking abruptly if the hospital has a 'no smoking' policy. Abrupt smoking cessation can affect the metabolism of drugs. Cigarette smoking induces the activity of human cytochromes P450 (CYP) 1A2 and 2B6. These enzymes metabolise several clinically important drugs, including clozapine, olanzapine and methadone. Decreased CYP1A2 activity after smoking cessation increases the risk of adverse drug reactions, with reports of increased toxicity from clozapine and olanzapine. Predicting the required dose reduction of drugs metabolised by CYP1A2 after smoking cessation is challenging. Therapeutic drug monitoring should be used when possible. Nicotine replacement therapy does not influence CYP1A2 activity.

DOI 10.18773/austprescr.2013.037
Citations Scopus - 9
2013 Thomas C, Martin J, Devic C, Bräuer-Krisch E, Diserbo M, Thariat J, Foray N, 'Impact of dose-rate on the low-dose hyper-radiosensitivity and induced radioresistance (HRS/IRR) response', International Journal of Radiation Biology, 89 813-822 (2013) [C1]

Purpose: To ask whether dose-rate influences low-dose hyper- radiosensitivity and induced radioresistance (HRS/IRR) response in rat colon progressive (PRO) and regressive (REG) ce... [more]

Purpose: To ask whether dose-rate influences low-dose hyper- radiosensitivity and induced radioresistance (HRS/IRR) response in rat colon progressive (PRO) and regressive (REG) cells. Methods: Clonogenic survival was applied to tumorigenic PRO and non-tumorigenic REG cells irradiated with 60 Co ¿-rays at 0.0025-500 mGy.min -1 . Both clonogenic survival and non-homologous end-joining (NHEJ) pathway involved in DNA double-strand breaks (DSB) repair assays were applied to PRO cells irradiated at 25 mGy.min -1 with 75 kV X-rays only. Results: Irrespective of dose-rates, marked HRS/IRR responses were observed in PRO but not in REG cells. For PRO cells, the doses at which HRS and IRR responses are maximal were dependent on dose-rate; conversely exposure times during which HRS and IRR responses are maximal (tHRSmax and tIRRmax) were independent of dose-rate. The tHRSmax and tIRRmax values were 23 ± 5 s and 66 ± 7 s (mean ± standard error of the mean [SEM], n = 7), in agreement with literature data. Repair data show that tHRSmax may correspond to exposure time during which NHEJ is deficient while tIRRmax may correspond to exposure time during which NHEJ is complete. Conclusion: HRS response may be maximal if exposure times are shorter than tHRSmax irrespective of dose, dose-rate and cellular model. Potential application of HRS response in radiotherapy is discussed. © 2013 Informa UK, Ltd.

DOI 10.3109/09553002.2013.800248
Citations Scopus - 11Web of Science - 9
2013 Fagan KJ, Irvine KM, Mcwhinney BC, Fletcher LM, Horsfall LU, Johnson LA, et al., 'BMI but not stage or etiology of nonalcoholic liver disease affects the diagnostic utility of carbohydrate-deficient transferrin', Alcoholism: Clinical and Experimental Research, 37 1771-1778 (2013)
DOI 10.1111/acer.12143
Citations Scopus - 7Web of Science - 7
2013 Chachay VS, Martin JH, Prins JB, Whitehead JP, O'Moore-Sullivan TM, Lee P, et al., 'Investigating the clinical effect of resveratrol in non-alcoholic fatty liver disease: A randomised, double blind, placebo-controlled trial', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 28 78-79 (2013) [E3]
2013 Scott IA, Gray LC, Martin JH, Pillans PI, Mitchell CA, 'Deciding when to stop: Towards evidence-based deprescribing of drugs in older populations', Evidence-Based Medicine, 18 121-124 (2013) [C3]

Minimising the harm from inappropriate prescribing in older populations is a major urgent concern for modern healthcare systems. In everyday encounters between prescribers and pat... [more]

Minimising the harm from inappropriate prescribing in older populations is a major urgent concern for modern healthcare systems. In everyday encounters between prescribers and patients, opportunities should be taken to identify patients at high risk of harm from polypharmacy and reappraise their need for specific drugs. Attempts to reconcile life expectancy, comorbidity burden, care goals and patient preferences with the benefits and harms of medications should be made in every patient at significant risk. Drugs identified by this process of reconciliation as conferring little or no benefit and/or excessive risk of harm should be candidates for discontinuation. Evidence supporting a structured approach to drug discontinuation (or deprescribing) is emerging, and while many barriers to deprescribing exist in routine practice, various enabling strategies can help overcome them.

DOI 10.1136/eb-2012-100930
Citations Scopus - 49
2013 Hubbard RE, Peel NM, Scott IA, Martin JH, Pillans P, Gray LC, 'Polypharmacy among older inpatients in Australia', AUSTRALASIAN JOURNAL ON AGEING, 32 24-24 (2013)
2013 Phillips LK, Peake JM, Zhang X, Hickman IJ, Briskey DR, Huang BE, et al., 'Postprandial total and HMW adiponectin following a high-fat meal in lean, obese and diabetic men', European Journal of Clinical Nutrition, 67 377-384 (2013) [C1]
DOI 10.1038/ejcn.2013.49
Citations Scopus - 9Web of Science - 10
2013 Dimeski G, Silvester B, Ungerer J, Johnson L, Martin JH, 'Policy change to improve pathology turnaround time and reduce costs - Possible to do both?', Biochemia Medica, 23 296-302 (2013) [C1]
DOI 10.11613/BM.2013.035
Citations Scopus - 3Web of Science - 2
2012 Martin JH, Valery PC, Moore SP, Coory M, Martin J, Garvey G, Green AC, 'Advanced stage at diagnosis and worse comorbidity explain overall survival disparities between Indigenous and non-Indigenous cancer patients in Queensland', Asia Pac J Clin Oncol, 8 212* (2012)
2012 Martin JH, Moore SP, Diaz A, Green AC, Garvey G, Coory M, Valery PC, 'Indigenous women with gynaecological cancers have poorer survival than non-Indigenous women: Explained by stage, comorbidity and treatment uptake', Asia Pacific Journal of Clinical Oncology, 8 321-321 (2012)
Citations Web of Science - 2
2012 Martin JH, Moore S, Green A, Garvey G, Corry M, Valery P, 'Breast Cancer diagnosis and patterns of treatment: does being indigenous make a difference?', Asia-Pacific Journal of Clinical Oncology, 8 304-304 (2012)
DOI 10.1111/ajco.12030
Citations Web of Science - 1
2012 Martin JH, Jellis C, Sacre J, Wright J, Jenkins C, Jeffriess L, et al., 'A Randomised Trial of Spironolactone use in Subclinical Diabetic Cardiomyopathy: Anti-Fibrotic Effects on Myocardial Structure and Function', Heart Lung and Circulation, 21 .-. (2012)
2012 Martin JH, Yamashiro Y, Gazarian M, Kling S, Nakamura H, Matsui A, et al., 'Drug Development: The Use of Unlicensed/Off-label Medicines in Pedatrics', Journal of Pediatric Gastroenterology and Nutrition, 55 506-510 (2012) [C1]
DOI 10.1097/MPG.0b013e318272af1f
Citations Scopus - 2Web of Science - 2
2012 Martin JH, Barras M, Yui NA, Kirkpatrick C, Kubler P, Norris R, 'Gentamicin Monitoring Practices in Teaching Hospitals ¿ Time to Undertake the Necessary Randomised Controlled Trial', Journal of Clinical Toxicology, 2 146-146 (2012) [C1]
DOI 10.4172/2161-0495.1000146
2012 Martin JH, Norris R, Barra M, 'Gentamicin Use ¿ More Clinical Outcome Evidence Needed', Journal of Clinical Toxicology, 2 e110-e110 (2012)
DOI 10.4172/2161-0495.1000e111
2012 Saleem M, Dimeski G, Kirkpatrick CM, Taylor PJ, Martin JH, 'Target Concentration Intervention in Oncology: Where Are We At?', THERAPEUTIC DRUG MONITORING, 34 257-265 (2012)
DOI 10.1097/FTD.0b013e3182557342
Citations Scopus - 19Web of Science - 16
2012 Roberts JA, Norris R, Paterson DL, Martin JH, 'Therapeutic drug monitoring of antimicrobials', BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 73 27-36 (2012) [C1]
DOI 10.1111/j.1365-2125.2011.04080.x
Citations Scopus - 96Web of Science - 80
2012 Scott IA, Gray LC, Martin JH, Mitchell CA, 'Minimizing Inappropriate Medications in Older Populations: A 10-step Conceptual Framework', AMERICAN JOURNAL OF MEDICINE, 125 529-+ (2012) [C1]
DOI 10.1016/j.amjmed.2011.09.021
Citations Scopus - 57Web of Science - 48
2012 Martin JH, Thelle DE, Ho KKY, Frazer IH, 'Diamantina Health Partners: integrating leadership in research, research translation, education and clinical care', MEDICAL JOURNAL OF AUSTRALIA, 196 237-239 (2012)
DOI 10.5694/mja11.11251
Citations Scopus - 3Web of Science - 3
2012 Martin JH, Coory MD, 'New medicines - urgent need to assess outcomes in special groups', MEDICAL JOURNAL OF AUSTRALIA, 196 433-433 (2012)
DOI 10.5694/mja12.10193
Citations Scopus - 4Web of Science - 4
2012 Martin JH, Coory M, Baade P, 'Challenges of an ageing and dispersed population for delivering cancer services in Australia: more than just doctors needed', INTERNAL MEDICINE JOURNAL, 42 349-351 (2012)
DOI 10.1111/j.1445-5994.2012.02746.x
Citations Scopus - 2Web of Science - 1
2012 Duley JA, Somogyi AA, Martin JH, 'The future of thiopurine pharmacogenomics', PHARMACOGENOMICS, 13 1549-1552 (2012)
DOI 10.2217/PGS.12.140
Citations Scopus - 7Web of Science - 6
2012 Scott IA, Gray LC, Martin JH, Mitchell CA, 'Effects of a drug minimization guide on prescribing intentions in elderly persons with polypharmacy.', Drugs Aging, 29 659-667 (2012)
DOI 10.1007/BF03262281
Citations Web of Science - 10
2012 Martin JH, Saleem M, Looke D, 'Therapeutic drug monitoring to adjust dosing in morbid obesity - a new use for an old methodology.', BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 73 685-690 (2012) [C1]
DOI 10.1111/j.1365-2125.2011.04159.x
Citations Scopus - 14Web of Science - 12
2012 Carroll J, Protani M, Walpole E, Martin JH, 'Effect of obesity on toxicity in women treated with adjuvant chemotherapy for early-stage breast cancer: a systematic review.', Breast Cancer Res Treat, 136 323-330 (2012) [C1]
DOI 10.1007/s10549-012-2213-3
Citations Scopus - 15Web of Science - 12
2012 Scott IA, Gray LC, Martin JH, Mitchell CA, 'Effects of a drug minimization guide on prescribing intentions in elderly persons with polypharmacy', Drugs and Aging, 29 659-667 (2012)
Citations Scopus - 14
2011 Martin JH, Jellis CL, Stanton T, Leano R, Marwick TH, 'Usefulness of at rest and exercise hemodynamics to detect subclinical myocardial disease in type 2 diabetes mellitus', American Journal of Cardiology, 107 615-621 (2011) [C1]
DOI 10.1016/j.amjcard.2010.10.024
Citations Scopus - 22Web of Science - 20
2011 Martin JH, Jacka C, Garvey G, Sabesan S, Ghandi M, Baxi S, et al., 'Closing the Divide in Indigenous cancer: Cancer brochures for Indigenous patients and their families', Asia Pacific Journal of Clinical Oncology, 7 147 (2011)
2011 Martin JH, Jellis C, Wrigh J, Kennedy D, Sacre J, Jenkins C, et al., 'Association of Imaging Markers of Myocardial Fibrosis with Metabolic and Functional Disturbances in Early Diabetic Cardiomyopathy', Circulation: Cardiovascular Imaging, 4 693-702 (2011) [C1]
DOI 10.1161/CIRCIMAGING.111.963587
Citations Scopus - 76Web of Science - 73
2011 Martin JH, Scott I, Mitchell C, Gray L, 'Optimising drug use in elderly populations ¿ pilot study of a drug minimization guide', Internal Medicine Journal, 41 14 (2011)
2011 Martin JH, Jellis C, Sacre JW, Haluska B, Jenkins C, Marwick TH, 'Myocardial Dysfunction and Metabolic Derangement in Type 2 Diabetes: Relationship with Procollagen Biomarkers of Myocardial Fibrosis', Journal American College of Cardiology, 57 860 (2011)
2011 Martin JH, Garvey G, Cunningham J, Valery PC, Condon J, Roder D, et al., 'Reducing the burden of cancer for Aboriginal and Torres Strait Islander Australians: time for a coordinated, collaborative, priority-driven, Indigenous-led research program', Medical Journal of Australia, 194 530-531 (2011)
Citations Scopus - 16Web of Science - 17
2011 McGloughlin S, Roberts JA, O'Donoghue S, Martin J, Briscoe S, Lipman J, 'Ganciclovir pharmacokinetics and suggested dosing in continuous venovenous haemodiafiltration', INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 37 90-92 (2011)
DOI 10.1016/j.ijantimicag.2010.10.003
Citations Scopus - 4Web of Science - 3
2011 Chachay VS, Kirkpatrick CMJ, Hickman IJ, Ferguson M, Prins JB, Martin JH, 'Resveratrol - pills to replace a healthy diet?', British Journal of Clinical Pharmacology, 72 27-38 (2011) [C1]
DOI 10.1111/j.1365-2125.2011.03966.x
Citations Scopus - 69Web of Science - 58
2011 Martin JH, Fay MF, Udy A, Roberts J, Kirkpatrick C, Ungerer J, Lipman J, 'Pitfalls of using estimations of glomerular filtration rate in an intensive care population', Internal Medicine Journal, 41 537-543 (2011) [C1]
DOI 10.1111/j.1445-5994.2009.02160.x
Citations Scopus - 36Web of Science - 32
Co-authors Michael Fay
2011 Mcneill GBS, Martin JH, 'How reliable is eGFR when calculating drug dosage in acute medical admissions?', Internal Medicine Journal, 41 327-331 (2011) [C1]
DOI 10.1111/j.1445-5994.2010.02307.x
Citations Scopus - 3Web of Science - 2
2011 Martin JH, Deacon CF, Gorrell MD, Prins JB, 'Incretin-based therapies - review of the physiology, pharmacology and emerging clinical experience', Internal Medicine Journal, 41 299-307 (2011) [C1]
DOI 10.1111/j.1445-5994.2011.02439.x
Citations Scopus - 48Web of Science - 46
2011 Martin JH, Kubler P, 'Treatment for pulmonary hypertension in Australia: too far too fast?', INTERNAL MEDICINE JOURNAL, 41 217-219 (2011)
DOI 10.1111/j.1445-5994.2011.02437.x
Citations Scopus - 1Web of Science - 1
2010 Jellis C, Sacre J, Martin J, Jenkins C, Haluska B, Marwick TH, 'Impaired Exercise Capacity in Diabetes: Procollagen Biomarkers Suggest Mechanism is Underlying Myocardial Fibrosis', CIRCULATION, 122 (2010)
2010 Martin JH, Norris R, Barras M, Roberts J, Morris R, Doogue M, Jones GRD, 'Guidelines Review - Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists', Clinical Biochemist Reviews, 31 21-24 (2010)
2010 Martin JH, Avent M, Pattullo C, Dines A, Kubler P, 'Drug Use Evaluation Services in Australia and New Zealand: A Neglected Area of Research?', J Pharm Pract Res, 40 15-18 (2010)
2010 Martin JH, Jellis CL, Narula J, Markwick TH, 'Assessment of nonischemic myocardial fibrosis', J. Am. Coll. Cardiol, 56 89-97 (2010)
Citations Scopus - 114Web of Science - 110
2010 Martin JH, Jellis CL, Stanton T, Leano R, Markwick TH, 'Subclinical myocardial disease in type 2 diabetes: Mechanistic insights from resting and exercise haemodynamics', Heart Lung and Circulation, 19 S196 (2010)
2010 Avent ML, Pattullo C, Dines A, Martin J, Kubler P, 'Drug use evaluation services in Australia and New Zealand: A neglected area of research?', Journal of Pharmacy Practice and Research, 40 15-18 (2010)

Aim: To describe the drug use evaluation (DUE) models used in hospitals in Australia and New Zealand. Method: 18 hospitals in Australia and New Zealand were identified as having D... [more]

Aim: To describe the drug use evaluation (DUE) models used in hospitals in Australia and New Zealand. Method: 18 hospitals in Australia and New Zealand were identified as having DUE pharmacist positions and 15 were willing to participate in the survey. DUE pharmacists were surveyed about the DUE process, structure, service implementation and their job descriptions. Results: 47% (7/15) of DUE pharmacists reported to the Director of Pharmacy, 33% (5/15) to the Drug and Therapeutics Committee and 20% (3/15) to the Director of Clinical Pharmacology. 73% (11/15) of DUE pharmacists were located in the hospital's pharmacy department. On average, a 0.8 full-time equivalent (range 0.2 to 2.5) pharmacist was dedicated to DUE activities per hospital with an average of 0.2 full-time equivalent (range 0 to 0.8) assigned to clinical activities. 79% (12/15) of hospitals only funded DUE pharmacist positions; 7% (1/15) funded combined pharmacist and pharmacy technician positions; 7% (1/15) funded combined pharmacist and rotating pharmacy intern positions; and 7% (1/15) funded clinical pharmacologist, nurse and pharmacist positions. 20% (3/15) of hospitals had a DUE subcommittee to coordinate DUE activities. All of the hospitals reported their DUE results to the Drug and Therapeutics Committees. Conclusion: A variety of DUE models exist in hospitals in Australia and New Zealand. Successful DUE services had a multidisciplinary approach with support and collaboration from medical, pharmacy, nursing and administrative staff.

DOI 10.1002/j.2055-2335.2010.tb00719.x
2010 Poulsen M, Middleton M, McQuitty S, Ramsay J, Gogna K, Martin J, et al., 'Comparison of a Commonwealth-initiated regional radiation oncology facility in Toowoomba with a Queensland Health facility', JOURNAL OF MEDICAL IMAGING AND RADIATION ONCOLOGY, 54 368-374 (2010) [C1]
DOI 10.1111/j.1754-9485.2010.02166.x
Co-authors Jarad Martin
2010 Martin JH, Norris R, Barras M, Roberts J, Morris R, Doogue M, Jones GRD, 'Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society Of Infectious Diseases Pharmacists.', The Clinical biochemist. Reviews, 31 21-24 (2010)
2010 Norris RL, Martin JH, Thompson E, Ray JE, Fullinfaw RO, Joyce D, et al., 'Current Status of Therapeutic Drug Monitoring in Australia and New Zealand: A Need for Improved Assay Evaluation, Best Practice Guidelines, and Professional Development', THERAPEUTIC DRUG MONITORING, 32 615-623 (2010)
DOI 10.1097/FTD.0b013e3181ea3e8a
Citations Scopus - 18Web of Science - 16
2010 Martin JH, Connelly KA, Boyle A, Kompa A, Zhang Y, Kelly D, et al., 'Effect of Atorvastatin on Cardiac Remodelling and Mortality in Rats Following Hyperglycemia and Myocardial Infarction', INTERNATIONAL JOURNAL OF CARDIOLOGY, 143 353-360 (2010) [C1]
DOI 10.1016/j.ijcard.2009.03.098
Citations Scopus - 6Web of Science - 6
Co-authors Andrew Boyle
2010 Phillips LK, Peake JM, Zhang X, Hickman IJ, Kolade O, Sacre JW, et al., 'The Effect of a High-Fat Meal on Postprandial Arterial Stiffness in Men with Obesity and Type 2 Diabetes', JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 95 4455-4459 (2010)
DOI 10.1210/jc.2010-0413
Citations Scopus - 14Web of Science - 13
2010 Protani M, Coory M, Martin JH, 'Effect of obesity on survival of women with breast cancer: systematic review and meta-analysis', BREAST CANCER RESEARCH AND TREATMENT, 123 627-635 (2010)
DOI 10.1007/s10549-010-0990-0
Citations Scopus - 393Web of Science - 368
2010 Hollingworth S, Duncan EL, Martin JH, 'Marked increase in proton pump inhibitors use in Australia', PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 19 1019-1024 (2010)
DOI 10.1002/pds.1969
Citations Scopus - 47Web of Science - 44
2010 Doogue MP, Martin JH, 'Whither therapeutic drug monitoring?', INTERNAL MEDICINE JOURNAL, 40 671-672 (2010)
DOI 10.1111/j.1445-5994.2010.02336.x
Citations Scopus - 1Web of Science - 1
2010 Jellis CL, Jenkins C, Leano R, Martin JH, Marwick TH, 'Reduced End-Systolic Pressure-Volume Ratio Response to Exercise A Marker of Subclinical Myocardial Disease in Type 2 Diabetes', CIRCULATION-CARDIOVASCULAR IMAGING, 3 443-449 (2010)
DOI 10.1161/CIRCIMAGING.109.934273
Citations Scopus - 10Web of Science - 9
2010 Scott KA, Martin JH, Inder WJ, 'Acidosis in the hospital setting: is metformin a common precipitant?', INTERNAL MEDICINE JOURNAL, 40 342-346 (2010)
DOI 10.1111/j.1445-5994.2009.01959.x
Citations Scopus - 12Web of Science - 12
2010 Martin JH, Fay MF, 'Surrogate end-points in clinical practice: are we providing worse care?', INTERNAL MEDICINE JOURNAL, 40 395-398 (2010)
DOI 10.1111/j.1445-5994.2010.02248.x
Citations Scopus - 6Web of Science - 6
Co-authors Michael Fay
2010 Siriwardane D, Woodman R, Hakendorf P, Martin JH, White GH, Ben-Tovim DI, Thompson CH, 'Stability of plasma creatinine concentrations in acute complex long-stay admissions to a general medical service', Clinical Medicine, Journal of the Royal College of Physicians of London, 10 540-543 (2010) [C1]
DOI 10.7861/clinmedicine.10-6-540
Citations Scopus - 5Web of Science - 5
2010 'ESICM 2010 WEDNESDAY SESSIONS 13 October 2010', Intensive Care Medicine, 36 326-433 (2010)
DOI 10.1007/s00134-010-2001-7
2009 Howell S, Coory M, Martin J, Duckett S, 'Using routine inpatient data to identify patients at risk of hospital readmission', BMC HEALTH SERVICES RESEARCH, 9 (2009)
DOI 10.1186/1472-6963-9-96
Citations Scopus - 58Web of Science - 52
2009 Martin JH, 'Advances in anticoagulants', Australian Doctor, . (2009)
2009 Martin JH, Doogue M, Somogyi A, Miners J, 'Prescribing in liver disease. Letter in response to Australian Prescriber', Australian Prescriber, 32 32(2):32-35 & 32(5):120 (2009)
2009 Martin JH, Doogue M, 'Editorial ¿ Guidelines or external regulation?', Internal Medicine Journal, 39 789-791 (2009)
2009 Martin JH, Ghiculescu A, 'Rapidly Progressive Severe Amiodarone-induced Hypothyroidism in an Elderly Female', Journal of Pharmacy Practice and Research, 39 140-141 (2009)
2009 Martin JH, Morris R, Beer C, Doogue M, 'Doctors and the pharmaceutical industry: time for a national policy?', Medical Journal of Australia, 191 189-190 (2009)
2009 Brien JAE, Reeve J, Sweidan M, Jayasuriya P, Martin J, 'Drug interaction alerts in dispensing and prescribing software', Journal of Pharmacy Practice and Research, 39 81-82 (2009)
2009 Ghiculescu RA, Martin J, 'Rapidly progressive severe amiodarone-induced hypothyroidism in an elderly female', Journal of Pharmacy Practice and Research, 39 140-141 (2009)

Background: Amiodarone-induced hyperthyroidism has been extensively reported in the Australian and international literature. However, amiodarone-induced hypothyroidism, although m... [more]

Background: Amiodarone-induced hyperthyroidism has been extensively reported in the Australian and international literature. However, amiodarone-induced hypothyroidism, although much less common, is also seen in clinical practice. Aim: To describe a case of rapidly progressive severe amiodarone-induced hypothyroidism complicated by myxoedema, cognitive decline and peripheral neuropathy in an elderly female. Clinical Details: An elderly female presented with a 3 to 6 month history of fatigue, cold intolerance and constipation. Her medical history was significant for type 2 diabetes, ischaemic heart disease and moderate mitral regurgitation complicated by severe left atrial dilatation and chronic atrial fibrillation. Outcomes: Her amiodarone was stopped and thyroxine commenced at 25 microgram daily. One week after admission her energy levels had improved to the point where she could safely manage at home. 6 months after amiodarone cessation she was euthyroid on thyroxine replacement and remained in rate controlled atrial fibrillation. Conclusion: Prescribers are reminded of the risk of serious thyroid morbidity associated with amiodarone use. Current recommendations include evaluation of risk against benefit with prolonged amiodarone therapy and periodic screening for early toxicity.

DOI 10.1002/j.2055-2335.2009.tb00438.x
2009 Doogue M, Martin J, 'Guidelines or external regulation?', INTERNAL MEDICINE JOURNAL, 39 789-791 (2009)
DOI 10.1111/j.1445-5994.2009.02050.x
2009 Martin JH, Mangiafico S, Kelly DJ, 'Role of Statins in Diabetes Complications', CURRENT DIABETES REVIEWS, 5 165-170 (2009)
DOI 10.2174/157339909788920901
Citations Scopus - 6Web of Science - 7
2009 Martin JH, Fay MF, Ungerer JP, 'eGFR - use beyond the evidence', MEDICAL JOURNAL OF AUSTRALIA, 190 197-199 (2009)
Citations Scopus - 16Web of Science - 13
Co-authors Michael Fay
2009 Sweidan M, Reeve JF, Brien J-AE, Jayasuriya P, Martin JH, Vernon GM, 'Quality of drug interaction alerts in prescribing and dispensing software', MEDICAL JOURNAL OF AUSTRALIA, 190 251-254 (2009)
Citations Scopus - 38Web of Science - 36
2009 Martin JH, Beer C, Morris RG, Doogue MP, 'Doctors and the pharmaceutical industry: time for a national policy?', MEDICAL JOURNAL OF AUSTRALIA, 191 189-190 (2009)
2009 Sweidan M, Reeve JF, Brien J-AE, Jayasuriya P, Martin JH, Vernon GM, 'Quality of drug interaction alerts in prescribing and dispensing software REPLY', MEDICAL JOURNAL OF AUSTRALIA, 191 358-359 (2009)
2009 Martin JH, 'Pharmacogenetics of warfarin - is testing clinically indicated?', AUSTRALIAN PRESCRIBER, 32 76-80 (2009)
Citations Scopus - 8Web of Science - 9
2009 Doogue M, Martin J, Miners J, Somogyi A, 'Prescribing in liver disease', AUSTRALIAN PRESCRIBER, 32 120-120 (2009)
Citations Scopus - 1Web of Science - 1
2009 Martin JH, Coory MD, Valery PC, Green AC, 'Association of diabetes with survival among cohorts of Indigenous and non-Indigenous Australians with cancer', CANCER CAUSES & CONTROL, 20 355-360 (2009)
DOI 10.1007/s10552-008-9249-z
Citations Scopus - 11Web of Science - 9
2009 Martin JH, Woods M, Mudge A, 'Old bugs new populations: an unusual presentation of pericarditis', INTERNAL MEDICINE JOURNAL, 39 850-851 (2009)
DOI 10.1111/j.1445-5994.2009.02079.x
Citations Scopus - 1Web of Science - 1
2008 Martin J, 'Statins and Congestive Heart Failure', CURRENT ATHEROSCLEROSIS REPORTS, 10 369-376 (2008)
DOI 10.1007/s11883-008-0058-3
Citations Scopus - 1Web of Science - 1
2008 Martin JH, Norris RL, Morris RG, Ray JE, Fullinfaw RO, Ilett KF, et al., 'A survey of Therapeutic Drug Monitoring in Australia and New Zealand', Clinical Biochemist Reviews, 29 Supp (iii) (2008)
2007 Kelly DJ, Zhang Y, Connelly K, Cox AJ, Martin J, Krum H, Gilbert RE, 'Tranilast attenuates diastolic dysfunction and structural injury in experimental diabetic cardiomyopathy', AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 293 H2860-H2869 (2007)
DOI 10.1152/ajpheart.01167.2006
Citations Scopus - 37Web of Science - 36
2007 Connelly KA, Kelly DJ, Zhang Y, Prior DL, Martin J, Cox AJ, et al., 'Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen-2)27 rat', CARDIOVASCULAR RESEARCH, 76 280-291 (2007)
DOI 10.1016/j.cardiores.2007.06.022
Citations Scopus - 52Web of Science - 54
2007 Martin JH, Connelly K, Kelly D, Zhang Y, Prior D, Cox A, et al., 'Functional, structural and molecular aspects of diastolic heart failure in the diabetic (mRen202) 27 rat', Cardiovascular Research, 76 280-291 (2007)
2007 Martin JH, Krum H, 'Statins and clinical outcomes in heart failure', CLINICAL SCIENCE, 113 119-127 (2007)
DOI 10.1042/CS20070031
Citations Scopus - 20Web of Science - 19
2007 Connelly KA, Kelly DJ, Martin JH, Zhang Y, Thai K, Krum H, Gilbert RE, 'Hyperglycaemia and an enhanced tissue RAS are necessary components in the pathogenesis of diabetic cardiac microvascular complications, mediated via PKC beta isoform', EUROPEAN HEART JOURNAL, 28 550-550 (2007)
2005 Martin JH, Kelly DJ, Mifsud SA, Zhang Y, Cox AJ, See F, et al., 'Tranilast attenuates cardiac matrix deposition in experimental diabetes: role of transforming growth factor-B¿', Cardiovascular Research, 65 694-701 (2005)
Citations Scopus - 73
2005 Martin JH, Denver R, Bailey M, Krum H, 'In Vitro inhibitory effects of atorvastatin on cardiac fibroblasts: implications for ventricular remodelling', Clinical and Experimental Pharmacology and Physiology, 32 697-701 (2005)
Citations Scopus - 60Web of Science - 52
2005 Martin JH, See F, Kompa A, Lewis DA, Krum H, 'Fibrosis as a Therapeutic Target Post-Myocardial Infarction. Current Pharmaceutical Design', Current Pharmaceutical Design, 11 477-487 (2005)
2005 See F, Kompa A, Martin J, Lewis DA, Krum H, 'Fibrosis as a therapeutic target post-myocardial infarction', Current Pharmaceutical Design, 11 477-487 (2005)

The extracellular matrix (ECM) is a dynamic microenvironment and a major contributor to the adverse ventricular remodelling that follows myocardial infarction (MI), via activation... [more]

The extracellular matrix (ECM) is a dynamic microenvironment and a major contributor to the adverse ventricular remodelling that follows myocardial infarction (MI), via activation of both direct pro-fibrotic pathways and matrix metalloproteinases (MMPs) that enhance collagenase activity. Reactive fibrosis, i.e. deposition of ECM materials remote from the region of the MI is clearly detrimental to ventricular function and contributory to adverse outcomes post-MI. Therefore, reversal of this process represents an important therapeutic target in post-MI management and treatment of established heart failure. A number of existing agents exert their beneficial effects in part via reductions in ECM deposition. Furthermore, specific anti-fibrotic drugs have been developed and are currently being explored for these and other cardiac conditions where pathological ECM deposition is felt to be contributory to disease progression. © 2005 Bentham Science Publishers Ltd.

DOI 10.2174/1381612053382098
Citations Scopus - 31
2003 Martin JH, Liew D, Krum H, 'Eplerenone (Pharmacia)', Curr Opin Investig Drugs, 4 316-322 (2003)
Citations Scopus - 1
2003 Martin J, Krum H, 'Erratum: Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class. (Drug Safety (2003) 26:1 (13-21))', Drug Safety, 26 893 (2003)
2003 Martin J, Krum H, 'Cytochrome P450 drug interactions within the HMG-CoA reductase inhibitor class - Are they clinically relevant?', DRUG SAFETY, 26 13-21 (2003)
DOI 10.2165/00002018-200326010-00002
Citations Scopus - 50Web of Science - 41
2003 Martin JH, Mourton SM, Nicholls MG, 'Severe hyperkalaemia with prescription of potassium-retaining agents in an elderly patient', New Zealand Medical Journal, 116 (2003)
Citations Scopus - 2
2002 Berakis A, Williams TJ, Naughton MT, Martin JH, Muhlmann M, Krum H, 'Altered sympathetic and parasympathetic activity in lung transplantation patients at rest and following autonomic perturbation', CHEST, 122 1192-1199 (2002)
DOI 10.1378/chest.122.4.1192
Citations Scopus - 14Web of Science - 12
2001 Martin JH, Begg EJ, Kennedy MA, Roberts R, Barclay ML, 'Is cytochrome P4502C9 genotype associated with NSAID gastric ulceration?', BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 51 627-630 (2001)
DOI 10.1046/j.0306-5251.2001.01398.x
Citations Scopus - 47Web of Science - 44
2001 Martin JH, 'Cytochrome P450 drug interactions: are they clinically relevent?', Australian Prescriber, 24 10-12 (2001)
Citations Scopus - 12
Co-authors Michael Fay
2001 Martin JH, 'Cytochrome P450 drug interactions', Australian Prescriber, 24 80-81 (2001)
2001 Martin JH, 'Eplerenone (GD Searle)', Current Opinion Invest Drugs, 2 521-524 (2001)
Citations Scopus - 11
2001 Martin JH, Fay MF, 'Capecitabine', Current Therapeutics, 42 49-51 (2001)
Co-authors Michael Fay
2001 Martin JH, 'The Heart Failure Journal Club: a review of publications on heart failure in American Heart Journal', Eur J Heart Failure, 3 125-137 (2001)
2001 Martin JH, 'Diltiazem-mediated inhibition of sildenafil metabolism may promote nitrate-induced hypotension', Internal Medicine Journal, 31 374-374 (2001)
2001 Martin JH, 'Role of valsartan and other angiotensin receptor blocking agents in the management of cardiovascular disease', Pharmacological Research, 46 203-212 (2001)
Citations Scopus - 18Web of Science - 12
2000 Martin JH, 'Drug prices not the whole story', Medical Observer, Melbourne, 24-24 (2000)
2000 Martin JH, Begg EJ, 'Reference pricing - is it in the public interest?', New Zealand Medical Journal, 113 422-425 (2000)
Citations Scopus - 8Web of Science - 6
1999 Martin JH, Begg EJ, 'OC'S - emotional journalism?', GP Weekly, . (1999)
1995 Martin JH, Abbott G, 'Serum sickness-like illness and antimicrobials in children', New Zealand Medical Journal, 108 123-124 (1995)
Show 205 more journal articles

Review (1 outputs)

Year Citation Altmetrics Link
1978 Ryan L, 'REVIEWS', Oceania (1978)

The Tasmanian Aborigines. By N. J. B. Plomley. A short account of them and some aspects of their life. Published by the author in association with the Adult Education Division, Ta... [more]

The Tasmanian Aborigines. By N. J. B. Plomley. A short account of them and some aspects of their life. Published by the author in association with the Adult Education Division, Tasmania. Launceston, 1977. viii + 72 pp. Copies available at $2.50 from the author, P.O. Box 1276 Launceston, Tasmania. 7250. © 1978 The University of Sydney

DOI 10.1002/j.1834-4461.1978.tb01377.x
Co-authors Lyndall Ryan, Nicholas Talley

Conference (69 outputs)

Year Citation Altmetrics Link
2017 Hayward KL, Valery PC, Martin JH, Karmakar A, Patel PJ, Horsfall LU, et al., 'Medication beliefs predict low medication adherence in people with decompensated cirrhosis', JOURNAL OF HEPATOLOGY, Amsterdam, NETHERLANDS (2017)
DOI 10.1016/S0168-8278(17)31113-3
2017 Hayward KL, Patel PJ, Valery PC, Horsfall LU, Li CY, Wright PL, et al., 'High-risk medication-related problems are prevalent in people with decompensated cirrhosis', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2017)
2017 Martin J, Lucas CJ, Reuter SE, Galettis P, 'Cannabinoid Toxicity Post Therapeutic Intraperitoneal Injection', Prague, Czech Republic (2017)
Co-authors Peter Galettis
2017 Nicoletti P, Aithal GP, Coulthard S, Andrade R, Einar BS, Dillon J, et al., 'Multiple HLA B*57 alleles, sharing the amino acid residue Valine(97), are associated with drug-induced liver injury due to flucloxacillin in a European population.', HEPATOLOGY, Washington, DC (2017)
2017 Hayward K, Patel PJ, Valery PC, Horsfall LU, Li CY, Wright PL, et al., 'Polypharmacy is Associated with High-Risk Medication-Related Problems in People with Decompensated Cirrhosis', HEPATOLOGY, Washington, DC (2017)
2016 Hayward KL, Cottrell WN, Karmakar A, Patel PJ, Horsfall LU, Martin JH, et al., 'Medication adherence in outpatients with decompensated cirrhosis', JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2016)
2015 Aithal GP, Nicoletti P, Bjornsson E, Lucena MI, Andrade RJ, Grove J, et al., 'HLA-A*33:01 is strongly associated with drug-induced liver injury (DILI) due to terbinafine and several other unrelated compounds', HEPATOLOGY (2015) [E3]
Citations Web of Science - 3
2015 Diaz A, Moore SP, Martin JH, Green AC, Garvey G, Valery PC, 'Comorbidities amongst Indigenous Cancer Patients: Impact on Treatment and Survival.', INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, Anchorage, AK (2015)
2015 Diaz A, Moore SP, Martin JH, Green AC, Coory M, Garvey G, Valery PC, 'Early Diagnosis and Improved Treatment Uptake in the First Year may Reduce Survival Disparities between Aboriginal and Torres Strait Islander and other Australian Women Diagnosed with Gynaecological Cancer', INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, Anchorage, AK (2015)
2015 Fay M, Sakoff J, Martin J, Rose S, Crozier S, Boyd A, et al., 'EPHA2 ANTIBODY INCREASES SENSITIVITY OF U87 GLIOBLASTOMA CELLS TO IRRADIATION', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Michael Fay, Jennette Sakoff
2015 Goulooze S, Martin J, 'MONTE-CARLO SIMULATIONS OF THE CLINICAL BENEFITS FROM THERAPEUTIC DRUG MONITORING OF SUNITINIB IN PATIENTS WITH GASTROINTESTINAL STROMAL TUMOURS', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Citations Scopus - 4
2015 Garg M, Galettis P, Goulooze S, Clingan P, Ranson M, Sakoff J, et al., 'THERAPEUTIC DRUG MONITORING FOR CANCER PATIENTS RECEIVING CHEMOTHERAPY', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2015) [E3]
Co-authors Stephen Ackland, Jennette Sakoff, Peter Galettis
2014 Martin JH, Tam L, Meiklejohn J, Garvey G, Adams J, Walpole E, et al., 'Supporting Aboriginal and Torres Strait people diagnosed with cancer to navigate the healthcare system', Abstracts COSA 2014, Melbourne (2014) [E3]
2014 Tam L, Meiklejohn J, Garvey G, Martin J, Adams J, Walpole E, et al., 'SUPPORTING ABORIGINAL AND TORRES STRAIT ISLANDER PEOPLE DIAGNOSED WITH CANCER TO NAVIGATE THE HEALTHCARE SYSTEM', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Michael Fay
2014 Linda N, Cheng M, Protani M, Martin J, Fay M, 'RELATIONSHIP BETWEEN OBESE WOMEN WITH BREAST CANCER, THEIR SOCIOECONOMIC STATUS AND COMORBIDITIES', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Michael Fay
2014 Cheng M, Linda N, Protani M, Carroll J, Fay M, Martin J, 'OBESITY A RISK FACTOR FOR CHEMOTHERAPY DOSE REDUCTION IN BREAST CANCER: A MULTI-CENTERED APPROACH', ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY (2014) [E3]
Co-authors Michael Fay
2013 Martin JH, Inder WJ, Thomas F, Sorbello J, Ho K, Torpy D, 'Cortisol status in patients with chronic non-malignant pain treated with opoids', Endocrine Reviews, San Francisco (2013) [E3]
2013 Martin JH, Hosein A, Lim Y, Day B, Stringer B, Rose S, et al., 'The use of valopric acid as an anti-glioma agent in combination with temozolomide and radiation', Proceedings of the 81st AANS Annual Scientific Meeting, New Orleans (2013) [E3]
2013 Martin JH, Hubbard R, Pillans P, Mitchell C, Scott I, Gray L, 'Polypharmacy among older inpatients in Australia', igital Ageing: A New Horizon for Health Care and Active Ageing, Seoul, South Korea (2013) [E3]
2012 Jellis CL, Wright J, Sacre J, Kennedy D, Jeffriess L, Fenwick J, et al., 'BACKSCATTER, T1 MAPPING OR PRO-COLLAGEN BIOMARKERS FOR NON-INVASIVE ASSESSMENT OF TREATMENT RESPONSE TO ANTI-FIBROTIC THERAPY IN SUBCLINICAL DIABETIC CARDIOMYOPATHY? A RANDOMIZED TRIAL', JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, Chicago, IL (2012)
DOI 10.1016/S0735-1097(12)61077-8
2012 Martin JH, Jellis C, Wright J, Scare J, Kennedy D, Haluska B, et al., 'Randomized trial of Spironolactone use in subclinical diabetic cardiomyopathy: anti-fibriotic effects on myocardial structure and function', Proceedings of ACC 2012, Chicago, IL (2012) [E3]
2012 Lucas CJ, Kubler P, Martin J, 'Is the process for approval of high cost drugs for off-formulary use leading to clinically appropriate outcomes?', Sydney, Australia (2012)
2012 Martin JH, Jellis C, Sacre J, Jenkins C, Haluska B, Markwick T, 'Relationship of pro-collagen biomarkers of myocardial fibrosis with myocardial dysfunction and metabolic derangement in type 2 diabetes', Abstracts of ESC Congress 2012, Munich (2012) [E3]
2012 Martin JH, Leung J, McLaughlin D, McKenzie S, Dobson A, 'Differences in breast cancer screening patters between women residing in rural and urban areas', Proceedings, Brisbane (2012) [E3]
2012 Martin JH, Valery PC, Moore SP, Coory M, Garvey G, Green AC, 'Advanced stage at diagnosis and worse comorbidity explain overall survival disparities between Indigenous and non-Indigenous cancer patients in Queensland', Proceedings of COSA 2012, Melbourne (2012) [E3]
2012 Martin JH, 'Advanced stage at diagnosis and worse comorbidity explain overall survival disparities between Indigenous and non-Indigenous cancer patients in Queensland', Impact through translation: cancer research informing practice, Brisbane (2012) [E3]
2012 Martin JH, Jellis C, Wright J, Scare J, Kennedy D, Haluska B, et al., 'A randomized trial of anti-fibriotic therapy in subclinical diabetic cardiomyopathy: T1 mapping and pro-collagen biomarkers for non-invasive assessment of treatment response', Proceedings of American College of Cardiology (ACC) 61st Annual Scientific Session, Chicago, IL (2012) [E3]
2012 Martin JH, Skinner T, Scott I, 'Diagnostic errors in older patients: a systematic review of the incidences and causes of thirteen prevalent conditions', Proceedings of IMSANZ 2012, Queenstown, New Zealand (2012) [E3]
2012 Martin JH, Skinner T, Scott I, 'Diagnostic errors in older patients: a systematic review of the incidences and causes of thirteen prevalent conditions', Proceedings of the 21st Annual RBWH Healthcare Symposium, Brisbane (2012) [E3]
2012 Martin JH, Chachay VS, Macdonald GA, O'Moore-Sullivan TM, Lee P, Franklin M, et al., 'A randomised, double-blind, placebo-controlled trial investigating the clinical effect of resveratrol in the management of obesity-related fatty liver disease', Proceedings of the International Postgraduate Symposium in Biomedical Sciences, Brisbane (2012) [E3]
2012 Martin JH, Lucas C, 'Is the process for approval of high cost drugs for off-formulary use leading to clinically appropriate and cost effective outcomes?', Proceedings of the Joint ASCEPT-APSA 2012 Conference, Sydney (2012) [E3]
2012 Martin JH, Chachay VS, Macdonald GA, O'Moore-Sullivan TM, Lee P, Franklin M, et al., 'A randomised, double blind, placebo-controlled trial investigating the clinical effect of resveratrol in the management of obesity-related fatty liver disease', Proceedings of Resveratrol 2012, Leicester, UK (2012) [E3]
2010 Martin JH, Jellis C, Wright J, Sacre J, Kennedy D, Haluska B, et al., 'Non-invasive quantification of myocardial fibrosis in diabetic cardiomyopathy: T1 mapping or integrated backscatter?', European Heart Journal Supplements, Copenhagen (2010) [E3]
2010 Martin JH, Putt MT, Roberts JA, Udy AA, Jarrett P, Salmon N, Lipman J, 'Assessment of adequacy of loading dose of phenytoin (PTN) in adult intensive care patients using population pharmacokinetics', ESICM 2010: Abstracts of Oral Presentations and Poster Sessions, Barcelona (2010) [E3]
2010 Phillips LK, Peake J, Zhang X, Hickman IJ, Huang BE, Simpson P, et al., 'The Effect of a High Fat Meal on Postprandial Arterial Stiffness in Obesity and Type 2 Diabetes.', ENDOCRINE REVIEWS, San Diego, CA (2010)
2010 Martin JH, 'Subclinical myocardial disease in type 2 diabetes: mechanistic insights from resting and exercise haemodynamics', Heart, Lung and Circulation: Abstracts of the Cardiac Society of Australia and New Zealand, Adelaide (2010) [E3]
DOI 10.1016/j.hlc.2010.06.475
2010 Martin JH, Ah Yui N, Kirkpatrick C, Barras M, Kubler P, Norris R, 'Optimising gentamicin use in a tertiary hospital setting', Proceedings of ASCEPT 2010, Melbourne (2010) [E3]
2010 Martin JH, Donovan P, Cardinal J, Salmon N, Kubler P, Norris R, 'Neutrophil gelatinous-associated lipocalin (NGAL) and cystatin C in acutely unwell general medical inpatients', Proceedings of ASCEPT 2010, Melbourne (2010) [E3]
2010 Martin JH, McNeil G, 'Is MDRD GFR reliable when calculating drug dosage in acute medical admissions?', Proceedings of WCIM 2010, Melbourne (2010)
2010 Putt MT, Roberts JA, Udy AA, Martin JH, Jarrett P, Salmon N, Lipman J, 'ASSESSMENT OF ADEQUACY OF LOADING DOSE OF PHENYTOIN (PTN) IN ADULT INTENSIVE CARE PATIENTS USING POPULATION PHARMACOKINETICS', INTENSIVE CARE MEDICINE, Barcelona, SPAIN (2010)
2009 Martin JH, Howell S, Coory M, 'The sensitivity of a local algorithm to predict risk of hospital readmission', Proceedings of 6th Health Services and Policy Research Conference, Perth (2009)
2009 Martin JH, Toleman J, Kubler P, Pattulo C, Holman J, Paterson D, 'Drug use evaluation of ticarcillin with clavulonic acid at the Royal Brisbane and Women's Hospital', Proceedings of ASCEPT 2009, Sydney (2009)
2009 Martin JH, 'Drug use evaluation of ceftriaxone at the Royal Brisbane and Women's Hospital', Proceedings of ASCEPT 2009, Sydney (2009) [E3]
2009 Martin JH, McNeil G, 'Is MDRD GFR reliable when calculating drug dosage in acute medical admissions?', Proceedings of the 3rd International Conference of the Society of Acute Medicine, London (2009)
2009 Martin JH, Patullo C, Kubler P, Avent M, 'The establishment of a quality use of medicines service at a large teaching hospital', Proceedings of the Society of Hospital Pharmacists of Australia Conference, Perth (2009)
2009 Martin JH, Patullo C, Kubler P, Avent M, 'The role of a QUM pharmacist in improving patient outcomes', Proceedings of the Society of Hospital Pharmacists of Australia Conference, Perth (2009)
2009 Martin JH, Norris R, MorrisR, Thompson E, Ray J, Barras M, et al., 'A survey of therapeutic drug monitoring in Australasia', Therapeutic Drug Monitoring: Abstracts of the 11th International Congress of Therapeutic Drug Monitoring and Clinical Toxicology, Montreal (2009) [E3]
2009 Norris R, Morris R, Thompson E, Ray J, Barras M, Jones G, Martin J, 'A Survey of Therapeutic Drug Monitoring in Australasia', THERAPEUTIC DRUG MONITORING, Montreal, CANADA (2009)
2008 Martin JH, Sweidan M, Reeve J, Brien J, Jayasuriya P, Vernon G, 'A study of the quality of drug interaction decision support in prescribing and dispensing software', Abstracts of the National Medicines Symposium 2008, Canberra (2008)
2008 Martin JH, Norris R, Morris R, Ilett K, Barras M, Jones G, 'A survey of therapeutic drug monitoring in Australia and New Zealand - preliminary results', Proceedings of the Australasian Association of Clinical Biochemists¿ 45th Annual Scientific Conference, Adelaide (2008) [E3]
2007 Martin JH, Choy SW, Desmond M, Lanteri M, Gock H, Hill P, 'An unusual cause of post-infectious glomerulonephritis', Nephrology, Gold Coast, Qld (2007) [E3]
DOI 10.1111/j.1440-1797.2007.00847.x
2007 Martin JH, Connelly K, Kelly D, Krum H, Gilbert R, Fennelly M, 'Functional, structural and molecular aspects of diastolic heart failure in the diabetic (MRen202) 27 rat', Cardiovascular Research, Vienna (2007) [E1]
2007 Martin JH, Brien JE, Jayasuriya P, Vernon G, Sweidan M, Reeve J, 'Drug interaction decision support in clinical software - user beware!', Proceedings of the SEAWP-ASCEPT Joint Annual Scientific Meeting, Adelaide (2007)
2006 Martin JH, Connelly K, Boyle A, Kelly DJ, Kompa A, Zhang M, et al., 'Hyperglycemia has a detrimental effect on cardiac remodelling and mortality after myocardial infarction: benefit of statin therapy', EUROPEAN HEART JOURNAL, Barcelona, SPAIN (2006)
Citations Web of Science - 1
2006 Martin JH, Connelly K, Boyle A, Kompa A, Zhang M, Kelly D, et al., 'Hyperglycemia has a detrimental effect on cardiac remodelling and mortality after myocardial infarction', Abstracts for the Cardiac Society of Australia and New Zealand Annual Scientific Meeting, Canberra (2006) [E3]
2006 Martin JH, Connelly K, Boyle A, Kompa A, Zhang M, Kelly D, et al., 'Hyperglycemia has a detrimental effect on cardiac remodelling and mortality after myocardial infaction: benefit of statin therapy', European Heart Journal, Barcelona (2006) [E3]
2004 Martin JH, 'Direct, dose-dependent antifibriotic effects of atorvastisin in human cardiac fibroblast cell culture', Journal of the American College of Cardiology, - (2004)
DOI 10.1016/S0735-1097(04)90679-1
2004 Martin JH, Kelly D, Misfud S, Zhang M, Krum H, Wilkinson-Berka J, Gilbert R, 'Tranilast dose-dependently attenuates extra-cellular matrix deposition in rats.', CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, Glasgow, SCOTLAND (2004)
2003 Martin JH, Cantwell D, Denver R, Hannan R, Way K, Kompa A, Krum H, 'Does protein kinase C-ß (PKC-ß) inhibition directly reduce collagen production from cardiac fibroblasts?', Proceedings of HBPRCA 2003, Sydney (2003)
2003 Martin JH, Denver R, Pepe S, Krum H, 'Dose-dependent anti-inflammatory effects of atorvastatin in rat and human cell culture', Proceedings of the 2003 Congress of the European Society of Cardiology, Vienna (2003)
2003 Martin JH, Kelly D, Mifsud S, Zhang Y, Krum H, Wilkinson-Berka J, Gilbert RE, 'Tranilast dose-dependent attenuates extra-cellular matrix deposition in rat myocardium', Proceedings of ASCEPT 2003, Sydney (2003)
2003 Martin JH, Harriss L, Windebank E, Brack J, Kamen P, Liew D, Krum H, 'Double-blind placebo-controlled, crossover study of effect of atorvastatin on autonomic function in patients with coronary artery disease', -, Adelaide (2003)
2003 Martin JH, 'Adverse reactions of cardiovascular drugs', -, Melbourne (2003)
2003 Martin JH, Denver R, Pepe S, Krum H, 'Dose-dependent and anti-fibriotic effects of atorvastatin in human cardiac fibroblast cell culture: a potential explanation for the beneficial, non-cholesterol effects of statins', -, Adelaide (2003)
2003 Martin JH, Denver R, Pepe S, Krum H, 'Direct, dose-dependent anti-fibrotic effects of atorvastatin in rat and human cardiac fibroblast cell culture', EUROPEAN HEART JOURNAL, VIENNA, AUSTRIA (2003)
DOI 10.1016/S0195-668X(03)95164-5
2002 Martin JH, Denver R, Pepe S, Krum H, 'Dose-dependent anti-fibriotic effects of atorvastatin in neonatal rat cardiac fibroblast cell culture: a potential contributor to the anti-remodelling effects of HMGCoA reductase inhibitors', ., Melbourne (2002)
2002 Martin JH, Krum H, Berakis A, Williams T, Muhlmann M, 'Alteration in sympathetic and parasympathetic function in lung transplant patients at rest and after autonomic pertubation', Proceedings of HBPRCA 2002, Melbourne (2002)
2001 Martin JH, Beckert L, Fontaine S, 'Involving medical registrars in teaching', Proceedings of ANZAME 2001, Wellington, New Zealand (2001)
1999 Martin JH, Begg EG, 'Reference pricing - what lessons can we learn?', ., Auckland (1999)
Show 66 more conferences
Edit

Grants and Funding

Summary

Number of grants 51
Total funding $18,374,232

Click on a grant title below to expand the full details for that specific grant.


20183 grants / $5,925,704

The NSW Clinical Cannabis Medicines Program$3,943,753

Funding body: NSW Ministry of Health

Funding body NSW Ministry of Health
Project Team Professor Jennifer Martin, Associate Professor Jenny Schneider, Doctor Peter Galettis, Doctor Catherine Lucas
Scheme Research Funds
Role Lead
Funding Start 2018
Funding Finish 2020
GNo G1701636
Type Of Funding C2210 - Aust StateTerritoryLocal - Own Purpose
Category 2210
UON Y

PREDICT — Pathway of Research to Evaluation of Dose-Individualised Cancer Therapy: Development of a national individualised cancer dosing program to both generate evidence and implement existing evi$1,961,951

Funding body: Cancer Council NSW

Funding body Cancer Council NSW
Project Team Professor Jennifer Martin, Conjoint Professor Stephen Ackland, Professor Howard Gurney, Professor Paul de Souza, Professor Michael Michael, Professor Alan Boddy, Professor Paul Scuffham, Dr Stephanie Reuter Lange, Doctor Peter Galettis
Scheme Pathways to a Cancer-Free Future
Role Lead
Funding Start 2018
Funding Finish 2022
GNo G1701238
Type Of Funding C3112 - Aust Not for profit
Category 3112
UON Y

A simple fingerprick and blood test to optimize chemotherapy dosing in oesophageal cancer$20,000

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Associate Professor Jenny Schneider, Doctor Peter Galettis, Professor Jennifer Martin, Conjoint Professor Stephen Ackland, Doctor Catherine Lucas
Scheme Project Grant
Role Investigator
Funding Start 2018
Funding Finish 2018
GNo G1800190
Type Of Funding C3120 - Aust Philanthropy
Category 3120
UON Y

20177 grants / $2,782,081

Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE): Quality and safety in the implementation of medicinal cannabis use in the community$2,481,102

Funding body: NHMRC (National Health & Medical Research Council)

Funding body NHMRC (National Health & Medical Research Council)
Project Team Professor Jennifer Martin, Dr N Solowij, Professor Jane Gunn, Associate Professor Nicholas Lintzeris, Professor Xu-Feng Huang, Professor Kathy Eagar, Professor Nanthi Bolan, Professor Paul Scuffham, Associate Professor Yvonne Bonomo, Doctor Amirali Popat
Scheme Centres of Research Excellence (CRE) - Centres of Clinical Research Excellence
Role Lead
Funding Start 2017
Funding Finish 2022
GNo G1601347
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON Y

Feasibility of minimally invasive, reliable and reproducible blood sampling techniques for chemotherapy dose optimisation in breast cancer$200,000

Funding body: National Breast Cancer Foundation

Funding body National Breast Cancer Foundation
Project Team Professor Jennifer Martin, Associate Professor Jenny Schneider, Conjoint Professor Stephen Ackland
Scheme Pilot Study Grant
Role Lead
Funding Start 2017
Funding Finish 2018
GNo G1600810
Type Of Funding Aust Competitive - Non Commonwealth
Category 1NS
UON Y

NSW PhD Scholarships Program 2017 - Berling$40,000

Funding body: NSW Ministry of Health

Funding body NSW Ministry of Health
Project Team Professor Jennifer Martin, Conjoint Professor Ian Whyte, Dr Ingrid Berling
Scheme PhD Scholarships Program
Role Lead
Funding Start 2017
Funding Finish 2018
GNo G1700886
Type Of Funding C2220 - Aust StateTerritoryLocal - Other
Category 2220
UON Y

Defining and predicting clinical toxicity in GBM patients undergoing temozolomide-radiation treatment: A multivariate study$25,000

Funding body: Mark Hughes Foundation

Funding body Mark Hughes Foundation
Project Team Doctor James Lynam, Doctor Jennette Sakoff, Professor Jennifer Martin, Doctor Lisa Lincz, Doctor Michael Fay, Doctor Peter Galettis
Scheme Research Funding
Role Investigator
Funding Start 2017
Funding Finish 2017
GNo G1700586
Type Of Funding C3120 - Aust Philanthropy
Category 3120
UON Y

Use of prochlorperazine to enable efficacy of targeted therapies in head and neck cancer$23,252

Funding body: Calvary Mater Newcastle

Funding body Calvary Mater Newcastle
Project Team Professor Jennifer Martin, Conjoint Professor Stephen Ackland
Scheme Project Grant
Role Lead
Funding Start 2017
Funding Finish 2017
GNo G1700472
Type Of Funding C3112 - Aust Not for profit
Category 3112
UON Y

Australian Centre for Cannabinoid Clinical and Research Excellence Education and Policy.$10,000

Funding body: University of Newcastle

Funding body University of Newcastle
Project Team Professor Jennifer Martin
Scheme Linkage Pilot Research Grant
Role Lead
Funding Start 2017
Funding Finish 2018
GNo G1701190
Type Of Funding Internal
Category INTE
UON Y

Analysis of qualitative data from interviews with Indigenous cancer patients$2,727

Funding body: QIMR Berghofer Medical Research Institute

Funding body QIMR Berghofer Medical Research Institute
Project Team Professor Jennifer Martin
Scheme Small Research Consultancy
Role Lead
Funding Start 2017
Funding Finish 2017
GNo G1700817
Type Of Funding C3112 - Aust Not for profit
Category 3112
UON Y

20166 grants / $84,636

Analysis of Cannabinoids$25,000

Funding body: University of Wollongong

Funding body University of Wollongong
Project Team Professor Jennifer Martin, Doctor Peter Galettis
Scheme Research Consultancy
Role Lead
Funding Start 2016
Funding Finish 2016
GNo G1601398
Type Of Funding Scheme excluded from IGS
Category EXCL
UON Y

Profiling Human Cardiac Stem Cells$21,745

Funding body: John Hunter Hospital Charitable Trust

Funding body John Hunter Hospital Charitable Trust
Project Team Professor Andrew Boyle, Professor Jennifer Martin
Scheme Research Grant
Role Investigator
Funding Start 2016
Funding Finish 2016
GNo G1600704
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Use of prochlorperazine to enable efficacy of targeted therapies in head and neck cancer (Equipment component).$13,252

Calvary Mater Newcastle 2016-2017 round of Research Grants $13,252. Coa lfields Equipment Fund.  Jennifer Martin and Stephen Ackland. Use of prochlorperazine to enable efficacy of targeted therapies in head and neck cancer (Equipment component). 

Funding body: Calvary Mater Newcastle

Funding body Calvary Mater Newcastle
Project Team

Jennifer Martin and Stephen Ackland

Scheme Coalfields Equipment Fund
Role Investigator
Funding Start 2016
Funding Finish 2017
GNo
Type Of Funding Other Public Sector - Local
Category 2OPL
UON N

Use of prochlorperazine to enable efficacy of targeted therapies in head and neck cancer (Equipment component)$10,000

Calvary Mater Newcastle 2016-2017 round of Research Grants $10,000. HCRA Clinical Cancer Fund. Jennifer Martin and Stephen Ackland. Use of prochlorperazine to enable efficacy of targeted therapies in head and neck cancer (Equipment component).

Funding body: Calvary Mater Newcastle

Funding body Calvary Mater Newcastle
Project Team

Jennifer Martin and Stephen Ackland

Scheme HCRA Clinical Cancer Fund
Role Investigator
Funding Start 2016
Funding Finish 2017
GNo
Type Of Funding Other Public Sector - Local
Category 2OPL
UON N

Use of prochlorperazine to enable efficacy of targeted therapies in head and neck cancer.$7,706

Calvary Mater Newcastle 2016-2017 round of Research Grants $7,706. James Lawrie Grant Scheme. Jennifer Martin and Stephen Ackland. Use of prochlorperazine to enable efficacy of targeted therapies in head and neck cancer

Funding body: Calvary Mater Newcastle 2016-2017 round of Research Grants

Funding body Calvary Mater Newcastle 2016-2017 round of Research Grants
Project Team

Jennifer Martin and Stephen Ackland

Scheme James Lawrie Grant Scheme
Role Investigator
Funding Start 2016
Funding Finish 2017
GNo
Type Of Funding Other Public Sector - Local
Category 2OPL
UON N

Effect of body size on chemotheraphy dose and blood concentrations in cancer$6,933

Funding body: Metro South Health

Funding body Metro South Health
Project Team Professor Jennifer Martin
Scheme Research Grant
Role Lead
Funding Start 2016
Funding Finish 2016
GNo G1601272
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

20152 grants / $514,400

High resolution fourier transform mass spectrometry platform for the discovery of novel cancer biomarkers and drug targets using label-free and isobaric-tagged approaches for quantitative proteomics.$500,000

Funding body: Cancer Institute NSW

Funding body Cancer Institute NSW
Project Team Professor Xu Dong Zhang, Doctor Matt Dun, Professor Jennifer Martin, Professor Hubert Hondermarck, Laureate Professor John Aitken, Doctor Nikki Verrills, Doctor Pradeep Tanwar, Laureate Professor Rodney Scott, Professor Maria Kavallaris, Dr Darren Saunders
Scheme Research Equipment Grant
Role Investigator
Funding Start 2015
Funding Finish 2016
GNo G1500599
Type Of Funding Other Public Sector - State
Category 2OPS
UON Y

Translational Addiction Reseach$14,400

Funding body: Hunter Medical Research Institute

Funding body Hunter Medical Research Institute
Project Team Conjoint Associate Professor Adrian Dunlop, Doctor Amanda Brown, Associate Professor Chris Dayas, Professor Jennifer Martin, Doctor Madeleine Hinwood
Scheme Research Grant
Role Investigator
Funding Start 2015
Funding Finish 2018
GNo G1500923
Type Of Funding C3112 - Aust Not for profit
Category 3112
UON Y

20142 grants / $266,651

Targeting existing therapies with innovative technology platforms to improve survival in brain cancer$200,000

Funding body: Cancer Council Queensland

Funding body Cancer Council Queensland
Scheme Project grant
Role Investigator
Funding Start 2014
Funding Finish 2014
GNo
Type Of Funding Not Known
Category UNKN
UON N

Effect of obesity on exposure to breast cancer chemotherapy: still a need to 'cap' the dose?$66,651

Funding body: University of Queensland

Funding body University of Queensland
Project Team Professor Jennifer Martin, Doctor Peter Galettis
Scheme Research Project
Role Lead
Funding Start 2014
Funding Finish 2016
GNo G1601146
Type Of Funding Grant - Aust Non Government
Category 3AFG
UON Y

20134 grants / $685,596

Improving systems and quality of cancer care in Aboriginal and Torres Strait Islander primary health care settings$640,096

Funding body: National Health & Medical Research Council

Funding body National Health & Medical Research Council
Scheme Project Grant
Role Investigator
Funding Start 2013
Funding Finish 2015
GNo
Type Of Funding Not Known
Category UNKN
UON N

University of Queensland Post Doctoral Scholarship for Women$37,500

Funding body: The University of Queensland

Funding body The University of Queensland
Scheme Scholarship
Role Lead
Funding Start 2013
Funding Finish 2015
GNo
Type Of Funding Internal
Category INTE
UON N

The clinical pharmacology of valproate$6,000

Funding body: Deutsche Akademische Austauschdienst

Funding body Deutsche Akademische Austauschdienst
Scheme Discovery project
Role Investigator
Funding Start 2013
Funding Finish 2015
GNo
Type Of Funding Not Known
Category UNKN
UON N

Clinical assessment of a predictive pharmacokinetic program for individualised vancomycin dosing in paediatrics$2,000

Funding body: Mater Hospitals, Brisbane

Funding body Mater Hospitals, Brisbane
Scheme Discovery project
Role Investigator
Funding Start 2013
Funding Finish 2013
GNo
Type Of Funding Not Known
Category UNKN
UON N

20129 grants / $3,146,502

The diamantina individualised oncology care centre$2,000,000

Funding body: Australian Cancer Research Foundation

Funding body Australian Cancer Research Foundation
Project Team

M. Brown

Scheme Cancer Research Grant
Role Investigator
Funding Start 2012
Funding Finish 2012
GNo
Type Of Funding Not Known
Category UNKN
UON N

Improving systems and quality of cancer care in Aboriginal and Torres Strait Islander primary health care settings$617,502

Funding body: National Health & Medical Research Council

Funding body National Health & Medical Research Council
Scheme Project Grant
Role Investigator
Funding Start 2012
Funding Finish 2012
GNo
Type Of Funding Aust Competitive - Commonwealth
Category 1CS
UON N

Effect of body size on chemotherapy dose and blood concentrations in cancer$150,000

Funding body: Princess Alexandra Hospital and District Health Service, QLD

Funding body Princess Alexandra Hospital and District Health Service, QLD
Scheme Early Career Fellowship
Role Lead
Funding Start 2012
Funding Finish 2012
GNo
Type Of Funding Not Known
Category UNKN
UON N

The effect of valproate on surrogate markers of prognosis in glioblastoma multiforme$105,000

Funding body: Royal Brisbane Hospital

Funding body Royal Brisbane Hospital
Project Team

M. Fay; I. Jeffree; A. Boyd; S. Rose; S. Robertson

Scheme Research Grant
Role Investigator
Funding Start 2012
Funding Finish 2012
GNo
Type Of Funding Not Known
Category UNKN
UON N

Indigenous community 'champion' project$79,000

Funding body: Cure Cancer Australia Foundation

Funding body Cure Cancer Australia Foundation
Project Team

Valery, P; Garvey, G; Walpole, E.

Scheme Project Grant
Role Investigator
Funding Start 2012
Funding Finish 2012
GNo
Type Of Funding Not Known
Category UNKN
UON N

Establishment of primary human liver cell isolation: a necessary model to understand hepatic disease$75,000

Funding body: Princess Alexandra Hospital and District Health Service, QLD

Funding body Princess Alexandra Hospital and District Health Service, QLD
Project Team

Elizabeth Powell

Scheme Foundation grant
Role Investigator
Funding Start 2012
Funding Finish 2012
GNo
Type Of Funding Not Known
Category UNKN
UON N

Effect of obesity on concentrations of breast cancer drugs and survival$75,000

Funding body: Princess Alexandra Hospital and District Health Service, QLD

Funding body Princess Alexandra Hospital and District Health Service, QLD
Scheme Foundation grant
Role Investigator
Funding Start 2012
Funding Finish 2012
GNo
Type Of Funding Not Known
Category UNKN
UON N

Are modern methods for aminoglycoside monitoring superior to existing approaches? a randomised controlled trial$35,000

Funding body: Royal Brisbane Hospital

Funding body Royal Brisbane Hospital
Project Team

M. Barris, I. Coombes, J. Roberts, D. Paterson

Scheme Research Grant
Role Investigator
Funding Start 2012
Funding Finish 2012
GNo
Type Of Funding Not Known
Category UNKN
UON N

Optimising pain management with fentanyl in patients with cancer$10,000

Funding body: Griffith Health Institute

Funding body Griffith Health Institute
Scheme MBOD Project Grant
Role Lead
Funding Start 2012
Funding Finish 2012
GNo
Type Of Funding Not Known
Category UNKN
UON N

20112 grants / $766,814

A comparative study: patterns of care, comorbidities and quality of life of Indigenous and non-Indigenous people with lung, head & neck, breast or gynaecological cancers$691,814

Funding body: National Health & Medical Research Council

Funding body National Health & Medical Research Council
Scheme Discovery project
Role Investigator
Funding Start 2011
Funding Finish 2013
GNo
Type Of Funding Not Known
Category UNKN
UON N

A new prescribing technology for older patients$75,000

Funding body: Princess Alexandra Hospital and District Health Service, QLD

Funding body Princess Alexandra Hospital and District Health Service, QLD
Project Team

Ian Scott, Len Gray

Scheme Foundation grant
Role Investigator
Funding Start 2011
Funding Finish 2011
GNo
Type Of Funding Not Known
Category UNKN
UON N

20102 grants / $1,779,000

Health workforce Australia capital agreement$1,100,000

Funding body: Redlands / QEII Hospital

Funding body Redlands / QEII Hospital
Scheme Discovery project
Role Lead
Funding Start 2010
Funding Finish 2010
GNo
Type Of Funding Not Known
Category UNKN
UON N

Patterns of care, comorbidities and quality of life in Indigenous people with cancer$679,000

Funding body: National Health & Medical Research Council

Funding body National Health & Medical Research Council
Scheme Project Grant
Role Lead
Funding Start 2010
Funding Finish 2010
GNo
Type Of Funding Not Known
Category UNKN
UON N

20092 grants / $74,848

Non-invasive cardiac imaging in the detection and assessment of subclinical diabetic heart disease$54,848

Funding body: National Heart Foundation of Australia

Funding body National Heart Foundation of Australia
Project Team

C. Jellis

Scheme NSW Cardiovascular Research Network Research Development Project Grant
Role Investigator
Funding Start 2009
Funding Finish 2009
GNo
Type Of Funding Not Known
Category UNKN
UON N

Relationship between obesity, chemotherapy dose and outcome in women with node positive breast cancer $20,000

Funding body: RBWH Clinical School, Faculty of Health Sciences, University of Queensland (Australia)

Funding body RBWH Clinical School, Faculty of Health Sciences, University of Queensland (Australia)
Scheme Discovery project
Role Lead
Funding Start 2009
Funding Finish 2009
GNo
Type Of Funding Not Known
Category UNKN
UON N

20082 grants / $40,000

The risk of cardiovascular disease post allogeneic bone marrow transplant: role of the peripheral blood mononuclear cell$30,000

Funding body: Clive & Vera Ramaciotti

Funding body Clive & Vera Ramaciotti
Scheme Project Grant
Role Investigator
Funding Start 2008
Funding Finish 2008
GNo
Type Of Funding Not Known
Category UNKN
UON N

Free phenytoin in severley unwell hospitalised populations$10,000

Funding body: Pathology Queensland

Funding body Pathology Queensland
Scheme Project Grant
Role Investigator
Funding Start 2008
Funding Finish 2008
GNo
Type Of Funding Not Known
Category UNKN
UON N

20071 grants / $40,000

Melbourne University Inter-faculty and Cross-disciplinary Steering Comittee Grant$40,000

Funding body: The University of Melbourne

Funding body The University of Melbourne
Project Team

Professor J. Prioetto

Scheme UMOSG Grant
Role Investigator
Funding Start 2007
Funding Finish 2007
GNo
Type Of Funding Not Known
Category UNKN
UON N

20063 grants / $2,105,000

NHMRC Clinical Centre for Research and Excellence in Clinical Science in Diabetes$2,000,000

Funding body: National Health & Medical Research Council

Funding body National Health & Medical Research Council
Project Team

Prof. J. Best

Scheme Discovery project
Role Investigator
Funding Start 2006
Funding Finish 2006
GNo
Type Of Funding Not Known
Category UNKN
UON N

Investigation of peripheral blood monocyte and adipose tissue macrophage function in obese subjects undertaking bariatric surgery$55,000

Funding body: Pfizer (USA)

Funding body Pfizer (USA)
Scheme Award
Role Lead
Funding Start 2006
Funding Finish 2006
GNo
Type Of Funding Not Known
Category UNKN
UON N

The role of the macrophage in Type 2 diabetes$50,000

Funding body: Royal Australasian College of Physicians

Funding body Royal Australasian College of Physicians
Scheme Research Establishment Award
Role Lead
Funding Start 2006
Funding Finish 2006
GNo
Type Of Funding Not Known
Category UNKN
UON N

20052 grants / $82,000

Melbourne University Early Career Grant$74,000

Funding body: The University of Melbourne Early Career Researcher Grant

Funding body The University of Melbourne Early Career Researcher Grant
Scheme The internal grant of the University of Melbourne
Role Lead
Funding Start 2005
Funding Finish 2006
GNo
Type Of Funding Not Known
Category UNKN
UON N

The role of the macrophage in the pathophysiology of diabetic and hypertensive cardiorenal disease$8,000

Funding body: St Vincent's Hospital Sydney

Funding body St Vincent's Hospital Sydney
Scheme Pilot Projects
Role Lead
Funding Start 2005
Funding Finish 2005
GNo
Type Of Funding Not Known
Category UNKN
UON N

20032 grants / $16,000

Australasian College of Clinical and Experimental Pharmacologists and Toxicologists Travel Prize$10,000

Funding body: Australasian College of Clinical and Experimental Pharmacologists and Toxicologists

Funding body Australasian College of Clinical and Experimental Pharmacologists and Toxicologists
Scheme Travel Grant
Role Lead
Funding Start 2003
Funding Finish 2003
GNo
Type Of Funding Not Known
Category UNKN
UON N

CSANZ Travelling Fellowship$6,000

Funding body: Cardiac Society of Australia and NewZealand

Funding body Cardiac Society of Australia and NewZealand
Scheme Travelling Fellowship
Role Lead
Funding Start 2003
Funding Finish 2003
GNo
Type Of Funding Not Known
Category UNKN
UON N

20011 grants / $55,000

Cardio Vascular Lipid (CVL) Research Grant$55,000

Funding body: National Heart Foundation of Australia

Funding body National Heart Foundation of Australia
Scheme Research Grant
Role Lead
Funding Start 2001
Funding Finish 2001
GNo
Type Of Funding Not Known
Category UNKN
UON N

19991 grants / $10,000

Cytochrome P450 2C9 genotype as a predictor for risk of peptic ulcer formation and complications with non-steroidal anti-inflammatory drugs$10,000

Funding body: Christchurch Medical Research Foundation

Funding body Christchurch Medical Research Foundation
Scheme Discovery Project
Role Investigator
Funding Start 1999
Funding Finish 1999
GNo
Type Of Funding External
Category EXTE
UON N
Edit

Research Supervision

Number of supervisions

Completed0
Current12

Total current UON EFTSL

Masters0.3
PhD1.1

Current Supervision

Commenced Level of Study Research Title Program Supervisor Type
2018 PhD Cannabinoids and Acute Pain Post Surgery PhD (Clinical Pharm), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2017 Masters Mitotane Pharmacodynamics in Adrenocortical Cancer in Children and Adults M Philosophy (Medicine), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2015 PhD Developmental and Environmental Determinants on Neonatal Pharmacology PhD (Clinical Pharm), Faculty of Health and Medicine, The University of Newcastle Co-Supervisor
2015 PhD Pharmacokinetics and Pharmacodynamics of Synthetic Cannabinoids in Humans PhD (Clinical Pharm), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2015 PhD Dosing paracetemol in patients with chronic liver disease Pharmacology, The University of Queensland Co-Supervisor
2014 Masters Combined pharmacogenetics and kinetics in hematology Pharmacology, University of Queensland Co-Supervisor
2014 Unknown Pharmacovigilance of immunology medications Pharmacology, University of Queensland Co-Supervisor
2014 PhD QT PROLONGATION IN MENTAL HEALTH PATIENTS: Contributory factors and clinical significance PhD (Clinical Pharm), Faculty of Health and Medicine, The University of Newcastle Principal Supervisor
2012 PhD Helping students structure knowledge for clinical use in PBL Pharmacology, University of Queensland Consultant Supervisor
2012 PhD Effect of obesity on mortality in breast cancer Pharmacology, University of Queensland Principal Supervisor
2010 PhD The role of resveratrol, a polyphenolic compound found in red grape skin, in the management of non-alcoholic fatty liver disease Pharmacology, University of Queensland Co-Supervisor
2010 PhD Combined effect of diabetes and obesity on survival in cancer Pharmacology, University of Queensland Co-Supervisor
Edit

Research Collaborations

The map is a representation of a researchers co-authorship with collaborators across the globe. The map displays the number of publications against a country, where there is at least one co-author based in that country. Data is sourced from the University of Newcastle research publication management system (NURO) and may not fully represent the authors complete body of work.

Country Count of Publications
Australia 192
United Kingdom 21
United States 20
China 9
Netherlands 8
More...
Edit

News

$1.96 million to personalise cancer treatment and change patient lives

March 28, 2018

Professor Jennifer Martin will develop a personalised chemotherapy dosing system for cancer patients to improve quality of life, reduce side effects and increase chance of survival.
Professor Jennifer Martin

UON researchers shine in 2017 NHMRC funding

October 11, 2017

University of Newcastle researchers have secured more than $6 million in the latest round of National Health and Medical Research Council (NHMRC) funding

ABC News: Who can get medical marijuana

February 24, 2017

This ABC News analysis explores the impact of the Federal Government's February 2017 approval of the importation of medicinal marijuana.

More to do before medicinal cannabis rollout

May 30, 2016

University of Newcastle's Professor Jennifer Martin outlines need for medical marijuana trials.
Deadly and illegal synthetic drugs

ABC 7.30: Potentially deadly and illegal synthetic drugs still available over the counter

February 23, 2016

Professor Jenny Martin and Michelle Williams are researchers in Clinical Phamacology and Toxicology at UON. They were recently featured on ABC's 7.30 explaining

UON researchers commence Medical Cannabis Trials

July 28, 2015

The University of Newcastle will undertake critical research into medical cannabis.

Professor Jennifer Martin

Position

Chair of Clinical Pharmacology
School of Medicine and Public Health
School of Medicine and Public Health
Faculty of Health and Medicine

Contact Details

Email jen.martin@newcastle.edu.au
Phone (02) 4042 0851
Fax (02) 4960 2088

Office

Building Hunter Medical Research Institute (HMRI)
Location HMRI 3 West Lot 1 Kookaburra Circuit New Lambton Heights NSW 2305

,
Edit